<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Treatment for primary postpartum haemorrhage - Mousa, HA - 2014 | Cochrane Library</title> <meta content="Treatment for primary postpartum haemorrhage - Mousa, HA - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003249.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Treatment for primary postpartum haemorrhage - Mousa, HA - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003249.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003249.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Treatment for primary postpartum haemorrhage" name="citation_title"/> <meta content="Hatem A Mousa" name="citation_author"/> <meta content="Leicester Royal Infirmary" name="citation_author_institution"/> <meta content="mousa339@hotmail.com" name="citation_author_email"/> <meta content="Jennifer Blum" name="citation_author"/> <meta content="Gynuity Health Projects" name="citation_author_institution"/> <meta content="Ghada Abou El Senoun" name="citation_author"/> <meta content="Queen's Medical Centre, Nottingham University Hospital" name="citation_author_institution"/> <meta content="Haleema Shakur" name="citation_author"/> <meta content="London School of Hygiene &amp; Tropical Medicine" name="citation_author_institution"/> <meta content="Zarko Alfirevic" name="citation_author"/> <meta content="The University of Liverpool" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD003249.pub3" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/02/12" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003249.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003249.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003249.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Rectal; Ergonovine [administration &amp; dosage]; Hysterectomy; Maternal Mortality; Misoprostol [administration &amp; dosage]; Oxytocics [administration &amp; dosage]; Oxytocin [administration &amp; dosage]; Postpartum Hemorrhage [drug therapy, surgery, *therapy]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003249.pub3&amp;doi=10.1002/14651858.CD003249.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003249.pub3&amp;doi=10.1002/14651858.CD003249.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003249.pub3&amp;doi=10.1002/14651858.CD003249.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003249.pub3&amp;doi=10.1002/14651858.CD003249.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003249.pub3&amp;doi=10.1002/14651858.CD003249.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003249.pub3&amp;doi=10.1002/14651858.CD003249.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003249.pub3&amp;doi=10.1002/14651858.CD003249.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003249.pub3&amp;doi=10.1002/14651858.CD003249.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003249.pub3&amp;doi=10.1002/14651858.CD003249.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003249.pub3&amp;doi=10.1002/14651858.CD003249.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003249.pub3&amp;doi=10.1002/14651858.CD003249.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003249.pub3&amp;doi=10.1002/14651858.CD003249.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003249.pub3&amp;doi=10.1002/14651858.CD003249.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003249.pub3&amp;doi=10.1002/14651858.CD003249.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003249.pub3&amp;doi=10.1002/14651858.CD003249.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003249.pub3&amp;doi=10.1002/14651858.CD003249.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003249.pub3&amp;doi=10.1002/14651858.CD003249.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003249.pub3&amp;doi=10.1002/14651858.CD003249.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003249.pub3&amp;doi=10.1002/14651858.CD003249.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003249.pub3&amp;doi=10.1002/14651858.CD003249.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003249.pub3&amp;doi=10.1002/14651858.CD003249.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003249.pub3&amp;doi=10.1002/14651858.CD003249.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003249.pub3&amp;doi=10.1002/14651858.CD003249.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="PrHmaMrX";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003249\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003249\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003249\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003249\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","fr","zh_HANS","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003249.pub3",title:"Treatment for primary postpartum haemorrhage",firstPublishedDate:"Feb 12, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pregnancy and Childbirth Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PrHmaMrX&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003249.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003249.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003249.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003249.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003249.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003249.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003249.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003249.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003249.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003249.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>18426 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003249.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003249.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003249.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003249.pub3/full#CD003249-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003249.pub3/full#CD003249-sec-0116"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003249.pub3/full#CD003249-sec-0029"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003249.pub3/full#CD003249-sec-0046"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003249.pub3/full#CD003249-sec-0047"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003249.pub3/full#CD003249-sec-0085"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003249.pub3/full#CD003249-sec-0113"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/table_n/CD003249StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/table_n/CD003249StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003249.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003249.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003249.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003249.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003249.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003249.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Treatment for primary postpartum haemorrhage</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003249.pub3/information#CD003249-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Hatem A Mousa</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003249.pub3/information#CD003249-cr-0003">Jennifer Blum</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003249.pub3/information#CD003249-cr-0004">Ghada Abou El Senoun</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003249.pub3/information#CD003249-cr-0005">Haleema Shakur</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003249.pub3/information#CD003249-cr-0006">Zarko Alfirevic</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/information/en#CD003249-sec-0124">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 12 February 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003249.pub3">https://doi.org/10.1002/14651858.CD003249.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003249-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003249-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003249-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003249-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003249-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003249-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003249-abs-0001" lang="en"> <section id="CD003249-sec-0001"> <h3 class="title" id="CD003249-sec-0001">Background</h3> <p>Primary postpartum haemorrhage (PPH) is one of the top five causes of maternal mortality in both developed and developing countries. </p> </section> <section id="CD003249-sec-0002"> <h3 class="title" id="CD003249-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of any intervention used for the treatment of primary PPH. </p> </section> <section id="CD003249-sec-0003"> <h3 class="title" id="CD003249-sec-0003">Search methods</h3> <p>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 August 2013). </p> </section> <section id="CD003249-sec-0004"> <h3 class="title" id="CD003249-sec-0004">Selection criteria</h3> <p>Randomised controlled trials comparing any interventions for the treatment of primary PPH. </p> </section> <section id="CD003249-sec-0005"> <h3 class="title" id="CD003249-sec-0005">Data collection and analysis</h3> <p>We assessed studies for eligibility and quality and extracted data independently. We contacted authors of the included studies to request more information. </p> </section> <section id="CD003249-sec-0006"> <h3 class="title" id="CD003249-sec-0006">Main results</h3> <p>Ten randomised clinical trials (RCTs) with a total of 4052 participants fulfilled our inclusion criteria and were included in this review. </p> <p>Four RCTs (1881 participants) compared misoprostol with placebo given in addition to conventional uterotonics. Adjunctive use of misoprostol (in the dose of 600 to 1000 mcg) with simultaneous administration of additional uterotonics did not provide additional benefit for our primary outcomes including maternal mortality (risk ratio (RR) 6.16, 95% confidence interval (CI) 0.75 to 50.85), serious maternal morbidity (RR 0.34, 95% CI 0.01 to 8.31), admission to intensive care (RR 0.79, 95% CI 0.30 to 2.11) or hysterectomy (RR 0.93, 95% CI 0.16 to 5.41).   </p> <p>Two RCTs (1787 participants) compared 800 mcg sublingual misoprostol versus oxytocin infusion as primary PPH treatment; one trial included women who had received prophylactic uterotonics, and the other did not. Primary outcomes did not differ between the two groups, although women given sublingual misoprostol were more likely to have additional blood loss of at least 1000 mL (RR 2.65, 95% CI 1.04 to 6.75). Misoprostol was associated with a significant increase in vomiting and shivering. </p> <p>Two trials attempted to test the effectiveness of estrogen and tranexamic acid, respectively, but were too small for any meaningful comparisons of pre‐specified outcomes. </p> <p>One study compared lower segment compression but was too small to assess impact on primary outcomes. </p> <p>We did not identify any trials evaluating surgical techniques or radiological interventions for women with primary PPH unresponsive to uterotonics and/or haemostatics. </p> </section> <section id="CD003249-sec-0007"> <h3 class="title" id="CD003249-sec-0007">Authors' conclusions</h3> <p>Clinical trials included in the current review were not adequately powered to assess impact on the primary outcome measures. Compared with misoprostol, oxytocin infusion is more effective and causes fewer side effects when used as first‐line therapy for the treatment of primary PPH. When used after prophylactic uterotonics, misoprostol and oxytocin infusion worked similarly. The review suggests that among women who received oxytocin for the treatment of primary PPH, adjunctive use of misoprostol confers no added benefit. </p> <p>The role of tranexamic acid and compression methods requires further evaluation. Furthermore, future studies should focus on the best way to treat women who fail to respond to uterotonic therapy. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003249-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003249-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003249-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003249-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003249-abs-0005">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003249-abs-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003249-abs-0007">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003249-abs-0003" lang="en"> <h3>Treatment for excessive bleeding after childbirth</h3> <p>After a woman gives birth, womb muscles contract, clamping down on the blood vessels and helping to limit bleeding when the placenta has detached. If the muscles do not contract strongly enough, very heavy bleeding (postpartum haemorrhage) can occur, which can be life threatening. These situations are common in resource‐poor countries, and maternal mortality is about 100 times higher than in resource‐rich countries. It is a very serious problem that requires effective treatments that might avoid the use of surgery to remove the womb (hysterectomy). This is often the last treatment option and leaves the woman unable to have more children. In most settings, women are given a drug at the time of birth (before excessive bleeding occurs) to reduce the likelihood of excessive blood loss. However, despite this intervention, some women bleed excessively, and this review looked to see what interventions might be used to reduce the amount of blood lost by these women. Treatment options include drugs to increase muscles contractions (such as oxytocin, ergometrine and prostaglandins like misoprostol), drugs to help with blood clotting (haemostatic drugs such as tranexamic acid and recombinant activated factor VII), surgical techniques (such as tying off or blocking of the uterine artery) and radiological interventions (to assist in blocking the main artery to the womb by using gel foams). </p> <p>The review identified 10 randomised controlled trials involving 4052 women. Seven of these trials looked at a drug called misoprostol, which is a prostaglandin and so works by increasing muscle contractions. Overall, the trials suggest that misoprostol does not work as well as oxytocin infusion, and it has more side effects. However, oxytocin needs to be kept in a refrigerator, and so in settings where refrigeration and infusions are not readily available, misoprostol can be used. </p> <p>Other clinical trials looked into using other types of drugs or squeezing the main artery that supplies blood to the woman. The number of women included in these studies was too small for any useful conclusions regarding their effectiveness and safety. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003249-sec-0116" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003249-sec-0116"></div> <h3 class="title" id="CD003249-sec-0117">Implications for practice</h3> <section id="CD003249-sec-0117"> <p>Primary PPH is a life‐threatening condition and availability of first‐aid treatment (IV line, parenteral fluids and uterotonics) is crucial. Current evidence suggests that intravenous oxytocin should be used as first‐line therapy for the treatment of primary PPH due to uterine atony. Evidence suggests that misoprostol is less effective than oxytocin and provides no additional uterotonic effect when used simultaneously with conventional oxytocin treatment. Efforts should be made to make injectable oxytocin available for use at deliveries occurring outside of facilities. When injectable oxytocin is not available, misoprostol can be used. </p> <p>Variation in dose regimens between the seven different misoprostol studies made it difficult for the review authors to draw clear conclusions regarding the most effective dose or route. As first‐line treatment, the largest body of evidence available supports the safety and effectiveness of an 800‐mcg sublingual dose. As an adjunct treatment to standard oxytocin infusion, various routes were examined, but none proved to be beneficial, so no regimen is suggested at this time. In general, the use of higher doses should be balanced against the likelihood of a greater incidence of maternal side effects associated with misoprostol. A system of "adverse event registration" might be helpful in identifying and tracking serious maternal morbidity and mortality associated with the use of all uterotonics in clinical practice. </p> <p>Use of tranexamic acid in routine clinical practice is under investigation. The results of one ongoing trial, the WOMAN trial, should be large enough to provide information on the effectiveness and safety of this drug for women with primary PPH (<a href="./references#CD003249-bbs2-0022" title="GulmezogluM , AlfirevicZ , ElbourneD , RobertsI . Tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind, placebo controlled trial (woman trial—Protocol Number ISRCTN76912190). International Journal of Gynecology &amp; Obstetrics2009;107(Suppl 2):S500. ShakurH , ElbourneD , GulmezogluM , AlfirevicZ , RonsmansC , AllenE , et al. The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial. Trials2010;11:40. ">Shakur 2010</a>). </p> <p>Lower segment compression is a simple and promising method, particularly when unwell patients with major haemorrhage are transferred between centres in low‐resource settings, where access to blood services is limited. Results from field studies of these methods will be included in a future review. </p> <p>We are unable to provide any guidance regarding the management of women with primary PPH who fail to respond to uterotonics and/or haemostatic drug therapies. However, it is logical to consider conservative surgical techniques and/or radiological interventions in an effort to avoid hysterectomy. The main challenge is to ensure that adequate clinical expertise is available at all times to determine when the conservative approach should be abandoned in favour of hysterectomy in a timely fashion. </p> </section> <h3 class="title" id="CD003249-sec-0118">Implications for research</h3> <section id="CD003249-sec-0118"> <p>High‐quality studies with adequate power are urgently needed to address our primary outcome measures. Future interventions addressing management of PPH at the community level would also be useful. Studies seeking to identify appropriate uterotonic management of primary PPH following home deliveries, particularly in developing countries, are of particular interest. </p> <p>Currently, no randomised data are available on the effectiveness of carbetocin, a long‐acting synthetic oxytocin analogue, but recent reports suggest that it may be of benefit in the prevention of primary PPH (<a href="./references#CD003249-bbs2-0128" title="SuLL , ChongYS , SamuelM . Carbetocin for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD005457.pub3] ">Su 2012</a>) and, therefore, further research would be justified. </p> <p>Three areas of research would be of particular interest for women with primary PPH unresponsive to uterotonics. First, further work is needed to identify the most effective tamponade procedures and uterine haemostatic suturing techniques in women with major primary PPH. Second, aortic compression devices and the non‐pneumatic antishock garment should be tested further in patients with major obstetrical haemorrhage. Finally, the benefits of interventional radiology for women at increased risk of bleeding during delivery and for those who bleed following childbirth should be critically evaluated in randomised trials. Ideally, first‐line uterotonics and second‐line surgical intervention trials should be conducted in both developed and developing countries. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003249-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003249-sec-0029"></div> <p>Nearly half a million women die annually across the world from causes related to pregnancy and childbirth (<a href="./references#CD003249-bbs2-0085" title="KhanKS , WojdylaD , SayL , GülmezogluAM , VanLookPF . WHO analysis of causes of maternal death: a systematic review. Lancet2006;367(9516):1066‐74. ">Khan 2006</a>; <a href="./references#CD003249-bbs2-0137" title="WHO , UNICEF , UNFPA. The World Bank World Health Organization (WHO) Press. Trends in Maternal Mortality: 1990 to 2008: Estimates Developed by WHO, UNICEF, UNFPA and The World Bank. Geneva: WHO, 2010. ">WHO 2010</a>). Approximately one‐quarter of these deaths are caused by complications of the third stage of labour, that is, excessive bleeding within the first 24 hours after delivery, also known as primary postpartum haemorrhage (PPH) (<a href="./references#CD003249-bbs2-0028" title="Abou ZahrC , RoystonE . Global Mortality: Global Factbook. Geneva: World Health Organization, 1991. ">Abou Zahr 1991</a>). In the developing world, PPH remains the leading cause of maternal death, accounting for one‐third of maternal deaths in Asia and Africa (<a href="./references#CD003249-bbs2-0085" title="KhanKS , WojdylaD , SayL , GülmezogluAM , VanLookPF . WHO analysis of causes of maternal death: a systematic review. Lancet2006;367(9516):1066‐74. ">Khan 2006</a>; <a href="./references#CD003249-bbs2-0137" title="WHO , UNICEF , UNFPA. The World Bank World Health Organization (WHO) Press. Trends in Maternal Mortality: 1990 to 2008: Estimates Developed by WHO, UNICEF, UNFPA and The World Bank. Geneva: WHO, 2010. ">WHO 2010</a>). In the United Kingdom (UK), the risk of death from obstetrical haemorrhage is about one in 100,000 deliveries (<a href="./references#CD003249-bbs2-0048" title="CantwellR , Clutton‐BrockT , CooperG , DawsonA , DrifeJ , GarrodD , et al. Saving Mothers’ Lives: reviewing maternal deaths to make motherhood safer: 2006–2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG: an international journal of obstetrics and gynaecology2011;118(Suppl 1):1‐203. ">Cantwell 2011</a>). </p> <section id="CD003249-sec-0030"> <h3 class="title" id="CD003249-sec-0030">Physiology</h3> <p>The uterus is composed of a unique interlacing network of muscle fibres known as 'myometrium'. The blood vessels that supply the placental bed pass through this latticework of uterine muscle (<a href="./references#CD003249-bbs2-0042" title="BaskettTF . A flux of the reds: evolution of active management of the third stage of labour. Journal of the Royal Society of Medicine2000;93:489‐93. ">Baskett 2000</a>). Myometrial contraction is the main driving force for both placental separation and haemostasis through constriction of these blood vessels. This blood‐saving mechanism is known as the 'physiological sutures' or 'living ligatures' (<a href="./references#CD003249-bbs2-0042" title="BaskettTF . A flux of the reds: evolution of active management of the third stage of labour. Journal of the Royal Society of Medicine2000;93:489‐93. ">Baskett 2000</a>). The physiological increase in clotting factors during labour helps to control blood loss after separation of the placenta. </p> <p>Active management of the third stage of labour has been standard practice in many parts of the world for many years (<a href="./references#CD003249-bbs2-0115" title="PrendivilleWJ , ElbourneDR . Care during the third stage of labour.. In: ChalmersI , EnkinM , KeirseMJNC editor(s). Effective care in pregnancy and childbirth. Oxford: Oxford University Press,, 1989:1145–69. ">Prendiville 1989</a>). It is suggested that prophylactic administration of a uterotonic will help to reduce blood loss and blood transfusion after delivery (<a href="./references#CD003249-bbs2-0043" title="BegleyCM , GyteGML , DevaneD , McGuireW , WeeksA . Active versus expectant management for women in the third stage of labour. Cochrane Database of Systematic Reviews2011, Issue 11. [DOI: 10.1002/14651858.CD007412] ">Begley 2011</a>). The role of early cord clamping and controlled cord traction in the reduction of bleeding is less clear; although it was once thought important to deliver the placenta quickly after uterotonic drug administration, to prevent it from being retained (<a href="./references#CD003249-bbs2-0091" title="McDonaldSJ , MiddletonP , DowswellT , MorrisPS . Effect of timing of umbilical cord clamping of term infants on maternal and neonatal outcomes. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD004074.pub3] ">McDonald 2013</a>), delayed cord clamping is now favoured. </p> <p>Blood loss up to 500 mL at delivery is regarded as 'physiological’. It is part of the normal mechanism that brings the mother's blood parameters to their normal non‐pregnant levels, and a healthy pregnant woman can cope with it with no difficulty (<a href="./references#CD003249-bbs2-0072" title="GyteG . The significance of blood loss at delivery. MIDIRS Midwifery Digest1992;2(1):88‐92. ">Gyte 1992</a>; <a href="./references#CD003249-bbs2-0120" title="RipleyDL . Uterine emergencies. Atony, inversion, and rupture. Obstetrics and Gynecology Clinics of North America1999;26(3):419‐34. ">Ripley 1999</a>). </p> </section> <section id="CD003249-sec-0031"> <h3 class="title" id="CD003249-sec-0031">Definition</h3> <p>Traditionally, primary PPH is defined as bleeding from the genital tract of 500 mL or more in the first 24 hours following delivery of the baby (<a href="./references#CD003249-bbs2-0056" title="CunninghamFG , MacDonaldPC , GantNF , LevenoKJ , GilstrapLC . Abnormalities of the third stage of labor. Williams Obstetrics. 19th Edition. Norwalk, CT: Appleton &amp; Lange, 1993. ">Cunningham 1993</a>, <a href="./references#CD003249-bbs2-0028" title="Abou ZahrC , RoystonE . Global Mortality: Global Factbook. Geneva: World Health Organization, 1991. ">Abou Zahr 1991</a>). Alternative cutoff levels of 600 mL (<a href="./references#CD003249-bbs2-0044" title="BeischerNA , MackayEV . Obstetrics and the Newborn. Eastbourne: Bailliere Tindall, 1986. ">Beischer 1986</a>), 1000 mL (<a href="./references#CD003249-bbs2-0047" title="BurchellRC . Postpartum haemorrhage. In: QuilliganES editor(s). Current Therapy in Obstetrics and Gynaecology. Philadelphia: WB Saunders, 1980. ">Burchell 1980</a>), 1500 mL (<a href="./references#CD003249-bbs2-0098" title="MousaH , AlfirevicZ . Major postpartum hemorrhage: survey of maternity units in the United Kingdom. Acta Obstetricia et Gynecologica Scandinavica2002;81(8):727‐30. ">Mousa 2002</a>), with a substantial fall in haematocrit or the need for blood transfusion (<a href="./references#CD003249-bbs2-0029" title="ACOG TechnicalBulletin . American College of Obstetricians and Gynecologists educational bulletin. Postpartum hemorrhage, Number 243. International Journal of Gynecology &amp; Obstetrics1998;61(1):79‐86. ">ACOG 1998</a>; <a href="./references#CD003249-bbs2-0053" title="CombsCA , MurphyEL , LarosRK . Factors associated with postpartum haemorrhage with vaginal birth. Obstetrics &amp; Gynecology1991;77:69‐76. ">Combs 1991</a>), have also been used. Unfortunately, underestimation of blood loss following delivery is a common problem, as visually (clinically) assessed bleeding underestimates measured blood loss by an average of 100 to 150 mL (<a href="./references#CD003249-bbs2-0116" title="PritchardJA , BaldwinRM , DickeyJC , WigginsKM . Blood volume changes in pregnancy and puerperium, II: red blood cell loss and changes in apparent blood volume during and following vaginal delivery, cesarean section, and cesarean section plus total hysterectomy. American Journal of Obstetrics and Gynecology1962;84:1271‐82. ">Pritchard 1962</a>; <a href="./references#CD003249-bbs2-0121" title="SloanNL , DurocherJ , AldrichT , BlumJ , WinikoffB . What measured blood loss tells us about postpartum bleeding: a systematic review. BJOG: an international journal of obstetrics and gynaecology2010;117(7):788‐800. ">Sloan 2010</a>; <a href="./references#CD003249-bbs2-0122" title="StaffordI , DildyGA , ClarkSL , BelfortMA . Visually estimated and calculated blood loss in vaginal and cesarean delivery. American Journal of Obstetrics and Gynecology2008;199(5):e511–e517. ">Stafford 2008</a>). Several methods have been proposed for measuring blood loss objectively, but they are used mainly for research purposes (<a href="./references#CD003249-bbs2-0121" title="SloanNL , DurocherJ , AldrichT , BlumJ , WinikoffB . What measured blood loss tells us about postpartum bleeding: a systematic review. BJOG: an international journal of obstetrics and gynaecology2010;117(7):788‐800. ">Sloan 2010</a>). In addition, women delivering by caesarean section lose more blood on average than women who have vaginal birth; therefore, 1000 mL is commonly used as a cutoff for significant blood loss after caesarean section. Overall, a trend towards increasing the rate of primary PPH has been seen in developed countries (<a href="./references#CD003249-bbs2-0086" title="KnightM , CallaghanWM , BergC , AlexanderS , Bouvier‐ColleMH , FordJB , et al. Trends in postpartum haemorrhage in high resource countries: a review and recommendations from the International Postpartum Haemorrhage Collaborative Group. BMC Pregnancy Childbirth2009;27(9):55. ">Knight 2009</a>). </p> </section> <section id="CD003249-sec-0032"> <h3 class="title" id="CD003249-sec-0032">Causes and risk factors</h3> <p>Several factors influence PPH rates, including whether blood loss is measured, how the third stage of labour is managed (e.g. the provision of uterotonic, uterine massage, controlled cord traction), obstetrical interventions carried out at the time of delivery (e.g. episiotomy, mode of delivery) and characteristics of the study population (<a href="./references#CD003249-bbs2-0043" title="BegleyCM , GyteGML , DevaneD , McGuireW , WeeksA . Active versus expectant management for women in the third stage of labour. Cochrane Database of Systematic Reviews2011, Issue 11. [DOI: 10.1002/14651858.CD007412] ">Begley 2011</a>; <a href="./references#CD003249-bbs2-0049" title="CarroliG , CuestaC , AbalosE , GulmezogluAM . Epidemiology of postpartum hemorrhage: a systematic review. Best Practice and Research. Clinical Obstetrics and Gynaecology2008;22(6):999‐1020. ">Carroli 2008</a>). Lack of efficient uterine contraction (uterine atony) is the most common cause of primary PPH. Other aetiological factors include retained parts of the placenta and vaginal or cervical tears. Uterine rupture, clotting disorders and uterine inversion are extremely rare but often very dramatic causes of heavy bleeding. Several investigators have attempted to identify factors that may pre‐dispose women to excessive blood loss after delivery. Examples of risk factors include first pregnancy (<a href="./references#CD003249-bbs2-0071" title="GilbertL , PorterW , BrownVA . Postpartum haemorrhage: a continuing problem. British Journal of Obstetrics and Gynaecology1987;94:67‐71. ">Gilbert 1987</a>; <a href="./references#CD003249-bbs2-0075" title="HallMH , HalliwellR , Carr‐HillR . Concomitant and repeated happenings of complications of the third stage of labour. British Journal of Obstetrics and Gynaecology1985;92:732‐8. ">Hall 1985</a>), maternal obesity (<a href="./references#CD003249-bbs2-0031" title="AisakaK , AndoS , KokuhoK , TawadaT , KanedaS , YoshimatsuJ , et al. Effects of obesity and weight gain during pregnancy on obstetrical factors. Acta Obstetrica et Gynaecologica Japonica1988;63:1851‐8. ">Aisaka 1988</a>), a large baby (<a href="./references#CD003249-bbs2-0126" title="StonesRW , PatersonCM , SaundersNSTG . Risk factors for major obstetric haemorrhage. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1993;48:15‐8. ">Stones 1993</a>), twin pregnancy (<a href="./references#CD003249-bbs2-0053" title="CombsCA , MurphyEL , LarosRK . Factors associated with postpartum haemorrhage with vaginal birth. Obstetrics &amp; Gynecology1991;77:69‐76. ">Combs 1991</a>; <a href="./references#CD003249-bbs2-0129" title="SuzukiS , HiraizumiY , MiyakeH . Risk factors for postpartum hemorrhage requiring transfusion in cesarean deliveries for Japanese twins: comparison with those for singletons. Archives of Gynecology and Obstetrics2012;286(6):1363‐7. ">Suzuki 2012</a>), prolonged or augmented labour (<a href="./references#CD003249-bbs2-0071" title="GilbertL , PorterW , BrownVA . Postpartum haemorrhage: a continuing problem. British Journal of Obstetrics and Gynaecology1987;94:67‐71. ">Gilbert 1987</a>), chorioamnionitis, pre‐eclampsia, maternal anaemia and antepartum haemorrhage (<a href="./references#CD003249-bbs2-0136" title="WettaLA , SzychowskiJM , SealsS , MancusoMS , BiggioJR , TitaAT . Risk factors for uterine atony/postpartum hemorrhage requiring treatment after vaginal delivery. American Journal of Obstetrics and Gynecology2013;209(1):51.e1‐51.e6. ">Wetta 2013</a>). High multiparity does not appear to be a risk factor in high‐ or low‐income countries, even after control for maternal age (<a href="./references#CD003249-bbs2-0063" title="DrifeJ . Management of primary postpartum haemorrhage. British Journal of Obstetrics and Gynaecology1997;104:275‐7. ">Drife 1997</a>; <a href="./references#CD003249-bbs2-0126" title="StonesRW , PatersonCM , SaundersNSTG . Risk factors for major obstetric haemorrhage. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1993;48:15‐8. ">Stones 1993</a>; <a href="./references#CD003249-bbs2-0133" title="TsuVD . Postpartum haemorrhage in Zimbabwe: a risk factor analysis. British Journal of Obstetrics and Gynaecology1993;100:327‐33. ">Tsu 1993</a>). Despite the identification of potential risk factors, primary PPH often occurs unpredictably in low‐risk women (<a href="./references#CD003249-bbs2-0099" title="MousaHA , CordingV , AlfirevicZ . Risk factors and interventions associated with major primary postpartum hemorrhage unresponsive to first‐line conventional therapy. Acta Obstetricia et Gynecologica Scandinavica2008;87(6):652‐61. ">Mousa 2008</a>). </p> </section> <section id="CD003249-sec-0033"> <h3 class="title" id="CD003249-sec-0033">Complications</h3> <p>The most important consequences of severe PPH include death, hypovolaemic shock, disseminated intravascular coagulopathy, renal failure, hepatic failure and adult respiratory distress syndrome (<a href="./references#CD003249-bbs2-0046" title="BonnarJ . Massive obstetric haemorrhage. Baillieres Best Practice and Research in Clinical Obstetrics and Gynaecology2000;14(1):1‐18. ">Bonnar 2000</a>). In low‐income countries, poor nutritional status, lack of easy access to treatment and inadequate intensive care and blood bank facilities are additional contributing factors that lead to high morbidity and mortality rates in these countries (<a href="./references#CD003249-bbs2-0085" title="KhanKS , WojdylaD , SayL , GülmezogluAM , VanLookPF . WHO analysis of causes of maternal death: a systematic review. Lancet2006;367(9516):1066‐74. ">Khan 2006</a>; <a href="./references#CD003249-bbs2-0137" title="WHO , UNICEF , UNFPA. The World Bank World Health Organization (WHO) Press. Trends in Maternal Mortality: 1990 to 2008: Estimates Developed by WHO, UNICEF, UNFPA and The World Bank. Geneva: WHO, 2010. ">WHO 2010</a>). As no definition of PPH has been universally accepted, the exact incidence of serious complications is difficult to ascertain (<a href="./references#CD003249-bbs2-0086" title="KnightM , CallaghanWM , BergC , AlexanderS , Bouvier‐ColleMH , FordJB , et al. Trends in postpartum haemorrhage in high resource countries: a review and recommendations from the International Postpartum Haemorrhage Collaborative Group. BMC Pregnancy Childbirth2009;27(9):55. ">Knight 2009</a>). </p> </section> <section id="CD003249-sec-0034"> <h3 class="title" id="CD003249-sec-0034">Management of primary PPH</h3> <p>Treatment for primary PPH requires a multidisciplinary approach. After exclusion of lower genital tract tears, in most cases, bleeding is due to uterine atony. Uterotonics that increase the efficiency of uterine contraction, including ergometrine and oxytocin, were introduced as first‐line therapy for atonic PPH in the 19th century. Women who continue to bleed require further assessment and interventions to control bleeding. These interventions may include additional uterotonics, haemostatic drugs, surgical interventions, radiological embolisation and/or compression devices (<a href="./references#CD003249-bbs2-0027" title="Abou El SenounG , SinghM , MousaHA , AlfirevicZ . Update on the new modalities on the prevention and management of postpartum haemorrhage. Fetal and Maternal Medicine Review2011;22(4):247‐64. ">Abou El Senoun 2011</a>). </p> <section id="CD003249-sec-0035"> <h4 class="title">A. Uterotonics</h4> <section id="CD003249-sec-0036"> <h5 class="title">Ergometrine</h5> <p>John Stearns (<a href="./references#CD003249-bbs2-0124" title="SteansJ . Observations on the secale cornutum or ergot, with directions for its use in parturition. Medical Research1822;5:90. ">Stearns 1822</a>) was the first to emphasise the use of ergots for PPH. Earlier, he wrote describing ergot's action: "It expedites lingering parturition ... The pains induced by it are peculiarly forcing ... In most cases you will be surprised with the suddenness of its operation" (<a href="./references#CD003249-bbs2-0123" title="StearnsJ . Account of the pulvis parturiens, a remedy for quickening childbirth. Medical Repository of New York1808;11:308‐9. ">Stearns 1808</a>). <a href="./references#CD003249-bbs2-0095" title="MoirJC . The action of ergot preparations on the puerperal uterus. BMJ1935;i:520‐3. ">Moir 1932</a> noticed that administration of aqueous ergot extract by mouth is associated with dramatic and vigorous uterine contractions, which were described as the 'John Stearns effect'. In 1935, Dudley and Moir were able to isolate the pure crystallised substance from the water‐soluble extract of ergot that was responsible for the 'John Stearns effect', and they called it 'ergometrine' (<a href="./references#CD003249-bbs2-0065" title="DudleyHW , MoirC . The substance responsible for the traditional clinical effect of ergot. BMJ1935;i:520‐3. ">Dudley 1935</a>). The isolation of a new water‐soluble extract of ergot was announced almost simultaneously from three other centres: in America (<a href="./references#CD003249-bbs2-0059" title="DavisME , AdherFL , RogersG , KharaschMS , LegaultRR . A new active principle in ergot and its effects on uterine motility. American Journal of Obstetrics and Gynecology1935;29:155‐67. ">Davis 1935</a>), the UK (<a href="./references#CD003249-bbs2-0131" title="ThompsonMR . The active constituents of ergot. A pharmacological and chemical study. Journal of the American Pharmaceutical Association1935;24:185‐96. ">Thompson 1935</a>) and Switzerland (<a href="./references#CD003249-bbs2-0125" title="StollA , BurckhardtE . L'ergobasine, nouvel alkaloide de l'ergot de seigle, solubile dans l'eau. Bulletin of Pharmaceutical Sciences1935;42:257‐66. ">Stoll 1935</a>). It turned out to be the same substance. The Americans called their preparation ergonovine, and the Swiss used the name ergobasine. Although the use of oxytocin is usually free of adverse effects, the use of ergometrine may be associated with nausea, vomiting and hypertension (<a href="./references#CD003249-bbs2-0029" title="ACOG TechnicalBulletin . American College of Obstetricians and Gynecologists educational bulletin. Postpartum hemorrhage, Number 243. International Journal of Gynecology &amp; Obstetrics1998;61(1):79‐86. ">ACOG 1998</a>). </p> </section> <section id="CD003249-sec-0037"> <h5 class="title">Oxytocin</h5> <p>In 1953, Vincent Du Vigneaud (<a href="./references#CD003249-bbs2-0064" title="Du VigneaudV , ResslerC , SwanJM , RobertsCW , KatsoyannisPG , GordonS . The synthesis of an octapeptide with the hormonal activity of oxytocin. Journal of the American Chemical Society1953;75:4879‐80. ">Du Vigneaud 1953</a>) identified the structure of oxytocin and was able to synthesise the hormone. By the 1980s, several randomised controlled trials and their meta‐analyses confirmed the effectiveness of active management of the third stage in reducing PPH (<a href="./references#CD003249-bbs2-0043" title="BegleyCM , GyteGML , DevaneD , McGuireW , WeeksA . Active versus expectant management for women in the third stage of labour. Cochrane Database of Systematic Reviews2011, Issue 11. [DOI: 10.1002/14651858.CD007412] ">Begley 2011</a>). Oxytocin and ergometrine have traditionally formed essential components of first‐line therapy in the management of primary PPH. Ergometrine (and the mixed drug combination of oxytocin and ergometrine) is contraindicated in women with a history of hypertension, heart disease, pre‐eclampsia or eclampsia. </p> <p>Carbetocin is a long‐acting synthetic oxytocin analogue that can be administered as a single dose either intravenously or intramuscularly; it produces a similar uterotonic effect as oxytocin. Intravenously administered carbetocin has a half‐life of 40 minutes (four to 10 times longer than oxytocin). Uterine activity persists for 120 minutes and 60 minutes following intramuscular and intravenous injection, respectively (<a href="./references#CD003249-bbs2-0081" title="HunterDJ , SchulzP , WassenaarW . Effect of carbetocin, a long acting oxytocin analogue in the postpartum uterus. Clinical Pharmacology and Therapeutics1992;52:60‐7. ">Hunter 1992</a>). In Europe, this drug is licenced only for prevention of uterine atony after caesarean section. Carbetocin is as effective, but more expensive, than oxytocin (<a href="./references#CD003249-bbs2-0127" title="SuLL , ChongYS , SamuelM . Oxytocin agonists for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD005457] ">Su 2007</a>). It may have unpleasant side effects, including headaches, tremor, hypotension, flushing, nausea, abdominal pain, pruritus and a feeling of warmth (<a href="./references#CD003249-bbs2-0117" title="RathW . Prevention of postpartum haemorrhage with the oxytocin analogue carbetocin. European Journal of Obstetrics &amp; Gynecology, and Reproductive Biology2009;147(1):15‐20. ">Rath 2009</a>). </p> </section> <section id="CD003249-sec-0038"> <h5 class="title">Prostaglandins</h5> <p>By the 1970s, the prostaglandin F2 alpha series was discovered by Sune Bergstrom, among others (<a href="./references#CD003249-bbs2-0045" title="BergstromS , RyhagER , SamuelsonB , SjovallJ . The structure of prostaglandin E, F1, F2. Acta Chemica Scandinavica1962;16:501‐2. ">Bergstrom 1962</a>). The 15‐methyl analogue of prostaglandin F2 alpha has been reported to have a high success rate if used alone (88%) or in combination with other uterotonic agents (95%) (<a href="./references#CD003249-bbs2-0108" title="OleenMA , MarianoJP . Controlling refractory atonic postpartum hemorrhage with hemabate sterile solution. American Journal of Obstetrics and Gynecology1990;162(1):205‐8. ">Oleen 1990</a>). Prostaglandin administration could be associated with unpleasant side effects, including vomiting, diarrhoea, hypertension and fever (<a href="./references#CD003249-bbs2-0108" title="OleenMA , MarianoJP . Controlling refractory atonic postpartum hemorrhage with hemabate sterile solution. American Journal of Obstetrics and Gynecology1990;162(1):205‐8. ">Oleen 1990</a>). </p> <p>Misoprostol, a methyl ester synthetic analogue of natural prostaglandin E1, is a thermo‐stable, inexpensive drug that can be used for prevention and treatment of PPH. It can be administered orally, sublingually, buccally, vaginally or rectally. A Cochrane systematic review of randomised trials of misoprostol versus injectable uterotonics in management of the third stage of labour suggests that the drug is less effective than injectable uterotonics in the prevention of severe PPH (blood loss ≥ 1000 mL) and has more adverse effects, including nausea, vomiting and diarrhoea (<a href="./references#CD003249-bbs2-0080" title="HofmeyrGJ , GülmezogluAM . Misoprostol for the prevention and treatment of postpartum haemorrhage. Best Practice &amp; Research Clinical Obstetrics &amp; Gynaecology2008;22(6):1025‐41. ">Hofmeyr 2008</a>; <a href="./references#CD003249-bbs2-0134" title="TunçalpÖ , HofmeyrGJ , GülmezogluAM . Prostaglandins for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD000494.pub4] ">Tunçalp 2012</a>). </p> <p>In most cases, uterotonic drugs will control postpartum bleeding, but if they do not, surgical intervention must be considered. </p> </section> </section> <section id="CD003249-sec-0039"> <h4 class="title">B. Haemostatic drugs</h4> <p>Haemostatic drugs, including tranexamic acid (<a href="./references#CD003249-bbs2-0039" title="AsAK , HagenP , WebbJB . Tranexamic acid in the management of postpartum haemorrhage. British Journal of Obstetrics and Gynaecology1996;103(12):1250‐1. ">As 1996</a>) and recombinant activated factor VII (rFVIIa) (<a href="./references#CD003249-bbs2-0096" title="MoscardoF , PerezF , de laRubiaJ , BalerdiB , LorenzoJI , SenentML , et al. Successful treatment of severe intra‐abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. British Journal of Haematology2001;114:174‐6. ">Moscardo 2001</a>), have been used for the treatment of intractable haemorrhage unresponsive to first‐ and second‐line therapies. Tranexamic acid is a systemic antifibrinolytic agent that is widely used in surgery to prevent clot breakdown (fibrinolysis) and therefore to reduce blood loss. It is a simple, inexpensive drug that requires no training for administration and can be used for prevention and treatment of primary PPH (<a href="./references#CD003249-bbs2-0039" title="AsAK , HagenP , WebbJB . Tranexamic acid in the management of postpartum haemorrhage. British Journal of Obstetrics and Gynaecology1996;103(12):1250‐1. ">As 1996</a>; <a href="./references#CD003249-bbs2-0067" title="FerrerP , RobertsI , SydenhamE , BlackhallK , ShakurH . Anti‐fibrinolytic agents in post partum haemorrhage: a systematic review. BMC Pregnancy Childbirth2009;15(9):29. ">Ferrer 2009</a>; <a href="./references#CD003249-bbs2-0101" title="NovikovaN , HofmeyrGJ . Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD007872] ">Novikova 2010</a>). It has a short half‐life of two hours.The use of tranexamic acid may be associated with side effects, including nausea, vomiting and diarrhoea. Other rare complications include hypotension, thrombosis, blurred vision, renal cortical necrosis and retinal artery obstruction (<a href="./references#CD003249-bbs2-0101" title="NovikovaN , HofmeyrGJ . Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD007872] ">Novikova 2010</a>; <a href="./references#CD003249-bbs2-0110" title="PeitsidisP , KadirRA . Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. Expert Opinion on Pharmacotherapy2011;12(4):503‐16. ">Peitsidis 2011</a>). </p> <p>Recombinant activated factor VII (rFVIIa; Novo Nordisk A/S, Bagsvaerd, Denmark) has also been successfully used for controlling life‐threatening PPH. It reduces blood loss through enhancement of tissue factor–dependent coagulation. It is effective in up to 80% of cases (<a href="./references#CD003249-bbs2-0036" title="AlfirevicZ , ElbourneD , PavordS , BolteA , VanGeijnH , MercierF , et al. Use of recombinant activated factorVII in primary postpartum hemorrhage: the Northern European registry 2000‐2004. Obstetrics and Gynecology2007;110(6):1270‐8. ">Alfirevic 2007</a>) but is quite expensive. Adverse events were observed in 2.5% of treated cases (<a href="./references#CD003249-bbs2-0068" title="FranchiniM , FranchiM , BergaminiV , MontagnanaM , SalvagnoGL , TargherG , et al. The use of recombinant activated FVII in postpartum haemorrhage. Clinical Obstetrics and Gynecology2010;53:219‐27. ">Franchini 2010</a>). Of note, all adverse events were thrombotic, including deep venous thrombosis, pulmonary embolism, cerebral thrombosis and myocardial infarction. </p> </section> <section id="CD003249-sec-0040"> <h4 class="title">C. Surgical interventions</h4> <p>Porro (<a href="./references#CD003249-bbs2-0113" title="PorroE . Della amputazione utero‐ovarica come complemento di taglio cesareo. Milan1876. ">Porro 1876</a>) was the first to describe caesarean hysterectomy to prevent death from uterine haemorrhage. However, the technique is associated with major complications and sterility. Active attempts have been made to introduce other conservative measures to avoid hysterectomy. </p> <section id="CD003249-sec-0041"> <h5 class="title">Uterine tamponade</h5> <p>Uterine packing, using several yards of wide gauze placed inside the uterine cavity, was one of the earliest methods introduced to achieve a tamponade effect to control primary PPH (<a href="./references#CD003249-bbs2-0066" title="EastmanNJ . Anomalies of the third stage of labor. William's Obstetrics. 10th Edition. New York: Appleton‐Century‐Crofts, 1950:917‐9. ">Eastman 1950</a>). It fell out of favour in the 1950s, as it was thought to conceal haemorrhage and cause infection (<a href="./references#CD003249-bbs2-0066" title="EastmanNJ . Anomalies of the third stage of labor. William's Obstetrics. 10th Edition. New York: Appleton‐Century‐Crofts, 1950:917‐9. ">Eastman 1950</a>). However, this technique re‐emerged in the 1980s and 1990s after these concerns were not confirmed (<a href="./references#CD003249-bbs2-0088" title="MaierRC . Control of postpartum haemorrhage with uterine packing. American Journal of Obstetrics and Gynecology1993;169:317‐23. ">Maier 1993</a>). </p> <p>Over the past decade, active attempts have been made to introduce better alternatives for uterine packing through the use of balloon tamponade, including Foley’s catheter (<a href="./references#CD003249-bbs2-0060" title="DeLoorJA , vanDamPA . Foley catheters for uncontrollable obstetric or gynecologic hemorrhage. Obstetrics &amp; Gynecology1996;88:737–8. ">De Loor 1996</a><i>)</i>, the Sengstaken‐Blakemore tube (<a href="./references#CD003249-bbs2-0050" title="ChanC , RazviK , ThamKF , ArulkumaranS . The use of a Sengstaken‐Blakemore tube to control post‐partum hemorrhage. International Journal of Gynaecology and Obstetrics1997;58:251–2. ">Chan 1997</a>),  the Rusch catheter (<a href="./references#CD003249-bbs2-0082" title="JohansonR , KumarM , ObhraiM , YoungP . Management of massive postpartum haemorrhage: use of a hydrostatic balloon catheter to avoid laparotomy. BJOG: an international journal of obstetrics and gynaecology2001;108(4):420‐2. ">Johanson 2001</a>), the Bakri balloon (<a href="./references#CD003249-bbs2-0041" title="BakriYN . Balloon device for control of obstetrical bleeding. European Journal of Obstetrics &amp; Gynecology, and Reproductive Biology1999;86:S84. ">Bakri 1999</a>) and the condom catheter (<a href="./references#CD003249-bbs2-0032" title="AkhterS , BegumMR , KabirJ . Condom hydrostatic tamponade for massive postpartum hemorrhage. International Journal of Gynecology &amp; Obstetrics2005;90:134–5. ">Akhter 2005</a>). After exclusion of a genital tract laceration, these procedures can be considered for control of obstetrical haemorrhage secondary to uterine atony, placenta accreta and placenta praevia. Overall, the difference between them is related mainly to balloon volume and the presence or absence of a cavity for draining blood. The overall success rate is around 80% (<a href="./references#CD003249-bbs2-0062" title="DoumouchtsisSK , PapageorghiouAT , ArulkumaranS . Systematic review of conservative management of postpartum hemorrhage: what to do when medical treatment fails. Obstetrical and Gynecological Survey2007;62(8):540‐7. ">Doumouchtsis 2007</a>; <a href="./references#CD003249-bbs2-0070" title="GeorgiouC . Balloon tamponade in the management of postpartum haemorrhage: a review. BJOG: an international journal of obstetrics and gynaecology2009;116:748‐57. ">Georgiou 2009</a>). Close observation of uterine size and the general condition of the woman is mandatory, as significant bleeding may occur distal to the bulb (<a href="./references#CD003249-bbs2-0033" title="AlamiaVJr , MeyerBA . Peripartum hemorrhage. Obstetrics and Gynecology Clinics of North America1999;26(2):385‐98. ">Alamia 1999</a>). </p> </section> <section id="CD003249-sec-0042"> <h5 class="title">Artery ligation and uterine compression sutures</h5> <p>Ligation of the uterine artery or its main supply (internal iliac artery) may be considered in selected cases (<a href="./references#CD003249-bbs2-0026" title="AbdRabboSA . Stepwise uterine devascularization: a novel technique for the management of uncontrollable postpartum hemorrhage with preservation of the uterus. American Journal of Obstetrics and Gynecology1994;171:694‐700. ">AbdRabbo 1994</a>; <a href="./references#CD003249-bbs2-0083" title="JouppilaP . Postpartum haemorrhage. Current Opinion in Obstetrics and Gynecology1995;7:446‐50. ">Jouppila 1995</a>). However, the latter may be technically difficult and is successful in less than 50% of cases (<a href="./references#CD003249-bbs2-0052" title="ClarkSL , PhelanJP , YehSY , BruceSR , PaulRH . Hypogastric artery ligation for obstetric hemorrhage. Obstetrics &amp; Gynecology1985;66(3):353‐6. ">Clark 1985</a>). </p> <p>Uterine compression sutures have recently been described (<a href="./references#CD003249-bbs2-0040" title="B‐LynchC , CokerA , LawalAH , AbuJ , CowenMJ . The B‐Lynch surgical technique for the control of massive postpartum haemorrhage: an alternative to hysterectomy? Five cases reported. British Journal of Obstetrics and Gynaecology1997;104(3):372‐5. ">B‐Lynch 1997</a>; <a href="./references#CD003249-bbs2-0051" title="ChoJH , JunHS , LeeCN . Hemostatic suturing technique for uterine bleeding during cesarean delivery. Obstetrics &amp; Gynecology2000;96(1):129‐31. ">Cho 2000</a>; <a href="./references#CD003249-bbs2-0076" title="HaymanRG , ArulkumaranS , SteerPJ . Uterine compression sutures: surgical management of postpartum hemorrhage. Obstetrics &amp; Gynecology2002;99(3):502‐6. ">Hayman 2002</a>; <a href="./references#CD003249-bbs2-0089" title="MarasingheJP , CondousG , SeneviratneHR , MarasingheU . Modified anchored B‐Lynch uterine compression suture for post partum bleeding with uterine atony. Acta Obstetricia et Gynecologica Scandinavica2011;90:280–3. ">Marasinghe 2011</a>; <a href="./references#CD003249-bbs2-0109" title="OuahbaJ , PikettyM , HuelC , AzarianM , FeraudO , LutonD , et al. Uterine compression sutures for postpartum bleeding with uterine atony. BJOG: an international journal of obstetrics and gynaecology2007;114(5):619‐22. ">Ouahba 2007</a>; <a href="./references#CD003249-bbs2-0112" title="PereiraA , NunesF , PedrosoS , SaraivaJ , RettoH , MeirinhoM . Compressive uterine sutures to treat postpartum bleeding secondary to uterine atony. Obstetrics and Gynecology2005;106(3):569‐72. ">Pereira 2005</a>; <a href="./references#CD003249-bbs2-0138" title="ZhengJ , XiongX , MaQ , ZhangX , LiM . A new uterine compression suture for postpartum haemorrhage with atony. BJOG: an international journal of obstetrics and gynaecology2011;118:370–4. ">Zheng 2011</a>). B‐Lynch was the first to describe a suture that runs through the full thickness of both uterine walls (anterior and posterior) (<a href="./references#CD003249-bbs2-0040" title="B‐LynchC , CokerA , LawalAH , AbuJ , CowenMJ . The B‐Lynch surgical technique for the control of massive postpartum haemorrhage: an alternative to hysterectomy? Five cases reported. British Journal of Obstetrics and Gynaecology1997;104(3):372‐5. ">B‐Lynch 1997</a>). When tied, the suture allows tight compression of the uterine walls and stops the bleeding (<a href="./references#CD003249-bbs2-0097" title="MousaHA , WalkinshawS . Major postpartum haemorrhage. Current Opinion in Obstetrics and Gynecology2001;13(6):595‐603. ">Mousa 2001</a>). Single or multiple stitches may be inserted at the same time and, according to the shape, they may be called brace suture (<a href="./references#CD003249-bbs2-0040" title="B‐LynchC , CokerA , LawalAH , AbuJ , CowenMJ . The B‐Lynch surgical technique for the control of massive postpartum haemorrhage: an alternative to hysterectomy? Five cases reported. British Journal of Obstetrics and Gynaecology1997;104(3):372‐5. ">B‐Lynch 1997</a>), simple brace (<a href="./references#CD003249-bbs2-0076" title="HaymanRG , ArulkumaranS , SteerPJ . Uterine compression sutures: surgical management of postpartum hemorrhage. Obstetrics &amp; Gynecology2002;99(3):502‐6. ">Hayman 2002</a>) or square sutures (<a href="./references#CD003249-bbs2-0051" title="ChoJH , JunHS , LeeCN . Hemostatic suturing technique for uterine bleeding during cesarean delivery. Obstetrics &amp; Gynecology2000;96(1):129‐31. ">Cho 2000</a>). Although they are thought to be effective in selected cases, unexpected occlusion of the uterine cavity with subsequent development of intrauterine synechiae (<a href="./references#CD003249-bbs2-0114" title="PoujadeO , GrossettiA , MougelL , CeccaldiP , DucarmeG , LutonD . Risk of synechiae following uterine compression sutures in the management of major postpartum haemorrhage. BJOG: an international journal of obstetrics and gynaecology2011;118:433–9. ">Poujade 2011</a>; <a href="./references#CD003249-bbs2-0118" title="RathatG , Do TrinhP , MercierG , ReyftmannL , DechanetC , BoulotP , et al. Synechia after uterine compression sutures. Fertility and Sterility2011;95(1):405‐9. ">Rathat 2011</a>) or infection (pyometra) has been reported (<a href="./references#CD003249-bbs2-0104" title="OchoaM , AllaireAD , StitelyML . Pyometria after hemostatic square suture technique. Obstetrics &amp; Gynecology2002;99(3):506‐9. ">Ochoa 2002</a>). The choice of the type of surgical intervention depends on several factors, paramount of which is the experience of the surgeon. Other factors include parity and desire for future children, the extent of the haemorrhage and the general condition of the woman (<a href="./references#CD003249-bbs2-0048" title="CantwellR , Clutton‐BrockT , CooperG , DawsonA , DrifeJ , GarrodD , et al. Saving Mothers’ Lives: reviewing maternal deaths to make motherhood safer: 2006–2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG: an international journal of obstetrics and gynaecology2011;118(Suppl 1):1‐203. ">Cantwell 2011</a>). </p> </section> </section> <section id="CD003249-sec-0043"> <h4 class="title">D. Radiological embolisation</h4> <p>Selective radiological embolisation of the bleeding vessel may be a therapeutic option in centres where interventional radiologists are available and the bleeding is not life threatening (<a href="./references#CD003249-bbs2-0038" title="ArulkumaranS , WalkerJJ , WatkinsonAF , NicholsonT , KesselD , PatelJ . The Role of Emergency and Elective Interventional Radiology in Postpartum Haemorrhage: Good Practice No 6. London: RCOG, 2007. ">Arulkumaran 2007</a>). In a systematic review, Doumouchtsis and colleagues evaluated the success rate of emergency embolisation for the control of major PPH. They reported a success rate of 91% (<a href="./references#CD003249-bbs2-0062" title="DoumouchtsisSK , PapageorghiouAT , ArulkumaranS . Systematic review of conservative management of postpartum hemorrhage: what to do when medical treatment fails. Obstetrical and Gynecological Survey2007;62(8):540‐7. ">Doumouchtsis 2007</a>). The procedure has many advantages including minimal morbidity and complication rates, shorter hospital stay and preservation of fertility; it can be carried out under local anaesthesia, and success can be verified. The procedure is not free of complications (<a href="./references#CD003249-bbs2-0062" title="DoumouchtsisSK , PapageorghiouAT , ArulkumaranS . Systematic review of conservative management of postpartum hemorrhage: what to do when medical treatment fails. Obstetrical and Gynecological Survey2007;62(8):540‐7. ">Doumouchtsis 2007</a>; <a href="./references#CD003249-bbs2-0111" title="PenninxJP , PasmansHL , OeiSG . Arterial balloon occlusion of the internal iliac arteries for treatment of life‐threatening massive postpartum haemorrhage: a series of 15 consecutive cases. European Journal of Obstetrics &amp; Gynecology, and Reproductive Biology2010;148(2):131‐4. ">Penninx 2010</a>; <a href="./references#CD003249-bbs2-0132" title="TsengJJ , HoJY , WenMC , HwangJI . Uterine necrosis associated with acute suppurative myometritis after angiographic selective embolization for refractory postpartum hemorrhage. American Journal of Obstetrics and Gynecology2011;204(6):e4‐e6. ">Tseng 2011</a>). Postprocedure fever is the most common complication and typically resolves within two to three days. Other complications include feet ischaemia, bladder and rectal wall necrosis and sciatic nerve injury (<a href="./references#CD003249-bbs2-0062" title="DoumouchtsisSK , PapageorghiouAT , ArulkumaranS . Systematic review of conservative management of postpartum hemorrhage: what to do when medical treatment fails. Obstetrical and Gynecological Survey2007;62(8):540‐7. ">Doumouchtsis 2007</a>). Late re‐bleeding is a rare but serious problem, and repeated embolisation or hysterectomy may be required. The use of interventional radiological techniques is limited by availability, and few centres have a 24‐hour trained, skilled team. Unlike with other procedures, an unstable patient has to be moved to the angiography suite (<a href="./references#CD003249-bbs2-0098" title="MousaH , AlfirevicZ . Major postpartum hemorrhage: survey of maternity units in the United Kingdom. Acta Obstetricia et Gynecologica Scandinavica2002;81(8):727‐30. ">Mousa 2002</a>). </p> </section> <section id="CD003249-sec-0044"> <h4 class="title">E. Non‐pneumatic antishock garment (NASG) and aortic compression device</h4> <p>In the 1900s, an inflatable pressure suit was developed by George Crile (<a href="./references#CD003249-bbs2-0135" title="VahediM , AyuyaoA , ParsaM , FreemanH . Pneumatic antishock garment‐associated compartment syndrome in uninjured lower extremities. Journal of Trauma1995;384(4):616‐8. ">Vahedi 1995</a>). After several modifications, it was used in the Vietnam War for resuscitation of soldiers with traumatic injuries (<a href="./references#CD003249-bbs2-0057" title='CutlerBS , DaggettWM . Application of the "G‐suit" to the control of hemorrhage in massive trauma. Annals of Surgery1971;173(4):511‐4. '>Cutler 1971</a>). In the 1970s, the G‐suit was modified into a half‐suit, which became known as MAST (military antishock trousers) or PASG (pneumatic antishock garment). From the 1970s, the National Aeronautics and Space Administration (NASA) contributed to the development of a “non‐pneumatic version” of the antishock garment. This was originally used for children with haemophilia but has since been developed into the garment known as the non‐pneumatic antishock garment (NASG) (<a href="./references#CD003249-bbs2-0074" title="HaggertyJ . Antishock garment. http://www.sti.nasa.gov/tto/spinoff1996/28. (accessed 20 February 2008). ">Haggerty 1996</a>). The NASG is a low‐technology pressure device that decreases blood loss, restores vital signs and has the potential to reduce adverse outcomes by helping women survive delays in receiving adequate emergency obstetrical care. Use of this garment as a temporising measure to stabilise women awaiting transfer to higher levels of care began in 2002 (<a href="./references#CD003249-bbs2-0077" title="HensleighPA . Anti‐shock garment provides resuscitation and haemostasis for obstetric haemorrhage. BJOG: an international journal of obstetrics and gynaecology2002;109(12):1377‐84. ">Hensleigh 2002</a>). Use of NASG among women with primary PPH in low‐income countries was associated with significant reduction of measured blood loss, severe maternal morbidities and mortality and emergency hysterectomy (<a href="./references#CD003249-bbs2-0092" title="MillerS , OjengbedeO , TuranJM , Morhason‐BelloIO , MartinHB , NsimaD . A comparative study of the non‐pneumatic anti‐shock garment for the treatment of obstetric hemorrhage in Nigeria. International Journal of Gynecology &amp; Obstetrics2009;107(2):121‐5. ">Miller 2009</a>; <a href="./references#CD003249-bbs2-0105" title="OjengbedeOA , Morhason‐BelloIO , GaladanciH , MeyerC , NsimaD , CamlinC , et al. Assessing the role of the non‐pneumatic anti‐shock garment in reducing mortality from postpartum hemorrhage in Nigeria. Gynecologic and Obstetric Investigation2011;71(1):66‐72. ">Ojengbede 2011</a>). </p> <p>External aortic compression is an emergency manoeuvre proposed to reduce PPH and permit time for resuscitation and control of bleeding. This technique involves compression of the abdominal aorta using a strong metal spring that is cylindrical in shape and is fixed in place by a leather belt wrapped around the waist (<a href="./references#CD003249-bbs2-0015" title="SoltanMH , FaragallahMF , MosabahMH , Al‐AdawyAR . External aortic compression device: the first aid for postpartum hemorrhage control. Journal of Obstetrics and Gynaecology Research2009;35(3):453‐8. ">Soltan 2009</a>). It is a cost‐effective and easily applied manoeuvre that allows satisfactory management of PPH (<a href="./references#CD003249-bbs2-0015" title="SoltanMH , FaragallahMF , MosabahMH , Al‐AdawyAR . External aortic compression device: the first aid for postpartum hemorrhage control. Journal of Obstetrics and Gynaecology Research2009;35(3):453‐8. ">Soltan 2009</a>).  </p> </section> </section> <section id="CD003249-sec-0045"> <h3 class="title" id="CD003249-sec-0045">Rationale for the review</h3> <p>The quest for fast, effective and safe interventions in cases of major primary PPH is the focus of this review. Other relevant published Cochrane reviews are <a href="./references#CD003249-bbs2-0043" title="BegleyCM , GyteGML , DevaneD , McGuireW , WeeksA . Active versus expectant management for women in the third stage of labour. Cochrane Database of Systematic Reviews2011, Issue 11. [DOI: 10.1002/14651858.CD007412] ">Begley 2011</a>, which compares active with expectant third‐stage management; <a href="./references#CD003249-bbs2-0134" title="TunçalpÖ , HofmeyrGJ , GülmezogluAM . Prostaglandins for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD000494.pub4] ">Tunçalp 2012</a>, <a href="./references#CD003249-bbs2-0054" title="CotterAM , NessA , TolosaJE . Prophylactic oxytocin for the third stage of labour. Cochrane Database of Systematic Reviews2001, Issue 4. [DOI: 10.1002/14651858.CD001808] ">Cotter 2001</a>, <a href="./references#CD003249-bbs2-0090" title="McDonaldSJ , AbbottJM , HigginsSP . Prophylactic ergometrine‐oxytocin versus oxytocin for the third stage of labour. Cochrane Database of Systematic Reviews2004, Issue 1. [DOI: 10.1002/14651858.CD000201] ">McDonald 2004</a>, <a href="./references#CD003249-bbs2-0128" title="SuLL , ChongYS , SamuelM . Carbetocin for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD005457.pub3] ">Su 2012</a>,  <a href="./references#CD003249-bbs2-0087" title="LiabsuetrakulT , ChoobunT , PeeyananjarassriK , IslamQM . Prophylactic use of ergot alkaloids in the third stage of labour. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD005456.pub2] ">Liabsuetrakul 2007</a> and <a href="./references#CD003249-bbs2-0107" title="OladapoOT , OkusanyaBO , AbalosE . Intramuscular versus intravenous prophylactic oxytocin for the third stage of labour. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD009332] ">Oladapo 2012b</a>, which consider the role of different prophylactic uterotonics in third‐stage management; <a href="./references#CD003249-bbs2-0100" title="NardinJM , WeeksA , CarroliG . Umbilical vein injection for management of retained placenta. Cochrane Database of Systematic Reviews2011, Issue 5. [DOI: 10.1002/14651858.CD001337] ">Nardin 2011</a>, which looks at the role of umbilical vein injection in the treatment of retained placenta; <a href="./references#CD003249-bbs2-0106" title="OladapoOT , FawoleB , BlumJ , AbalosE . Advance misoprostol distribution for preventing and treating postpartum haemorrhage. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD009336] ">Oladapo 2012a</a>, which evaluates advance community distribution of misoprostol for preventing or treating PPH; <a href="./references#CD003249-bbs2-0101" title="NovikovaN , HofmeyrGJ . Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD007872] ">Novikova 2010</a>, which evaluates the place of tranexamic acid for preventing PPH and <a href="./references#CD003249-bbs2-0034" title="AlexanderJ , ThomasP , SangheraJ . Treatments for secondary postpartum haemorrhage. Cochrane Database of Systematic Reviews2002, Issue 1. [DOI: 10.1002/14651858.CD002867] ">Alexander 2002</a>, which is examining drug treatment for secondary PPH. The current review focuses primarily on atonic primary PPH. Management of haemorrhage due to laceration of the genital tract is outside the scope of this review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003249-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003249-sec-0046"></div> <p>To determine the effectiveness of any intervention used for the treatment of primary postpartum haemorrhage. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003249-sec-0047" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003249-sec-0047"></div> <section id="CD003249-sec-0048"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003249-sec-0049"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials of treatment for primary postpartum haemorrhage (PPH).</p> </section> <section id="CD003249-sec-0050"> <h4 class="title">Types of participants</h4> <p>Women after delivery following a pregnancy of at least 24 weeks' gestation with a diagnosis of primary PPH, regardless of mode of delivery (vaginal or caesarean section) or other aspects of third‐stage management. Initially, our protocol stipulated that only studies in which primary PPH was defined as blood loss greater than 500 mL would be included. As it may be difficult to obtain an accurate measurement of blood loss before recruitment, we expanded our inclusion criteria to include trials in which PPH was defined in one of the following ways: </p> <p> <ul id="CD003249-list-0001"> <li> <p>women with blood loss of 500 mL or more and/or</p> </li> <li> <p>women with primary PPH requiring blood transfusion and/or blood products and/or</p> </li> <li> <p>women with a clinical diagnosis of primary PPH (as defined by trialists).</p> </li> </ul> </p> <section id="CD003249-sec-0051"> <h5 class="title">Exclusion criteria</h5> <p> <ul id="CD003249-list-0002"> <li> <p>Women with PPH with gestational age less than 24 weeks.</p> </li> </ul> </p> </section> </section> <section id="CD003249-sec-0052"> <h4 class="title">Types of interventions</h4> <p>Eligible interventions included:</p> <p> <ul id="CD003249-list-0003"> <li> <p>uterotonic agents that encourage uterine contractility (such as oxytocin, ergometrine, carbetocin and prostaglandins); </p> </li> <li> <p>haemostatic agents that influence the clotting cascade (tranexamic acid and recombinant activated factor VII); </p> </li> <li> <p>surgical interventions such as uterine packing or intrauterine catheter insertion, artery ligation, uterine compression sutures and/or hysterectomy; </p> </li> <li> <p>interventional radiology (X‐ray–guided embolisation);</p> </li> <li> <p>non‐pneumatic antishock garment (NASG) and aortic compression device; and</p> </li> <li> <p>any other medical or surgical intervention.</p> </li> </ul> </p> <p>Main comparisons included the following interventions.</p> <p> <ul id="CD003249-list-0004"> <li> <p>Uterotonics versus control (no intervention) or placebo.</p> </li> <li> <p>One uterotonic agent versus other single or multiple uterotonic drugs.</p> </li> <li> <p>Haemostatic drugs versus other treatment, or versus control or placebo.</p> </li> <li> <p>Uterine packing or balloon tamponade (e.g. Foley, hydrostatic catheter) versus other treatment, or versus control or placebo. </p> </li> <li> <p>Uterine compression sutures (e.g. brace, square) versus other treatment, or versus control or placebo. </p> </li> <li> <p>Vessel ligation versus other treatment, or versus control or placebo.</p> </li> <li> <p>Hysterectomy versus other treatment, or versus control or placebo.</p> </li> <li> <p>Radiological embolisation versus other treatment, or versus control or placebo.</p> </li> <li> <p>Non‐pneumatic antishock garment (NASG) and aortic compression device versus other treatment, or versus control or placebo. </p> </li> <li> <p>Any other medical or surgical intervention used for treatment of primary PPH versus other treatment or versus control or placebo. </p> </li> </ul> </p> <p><b>Control group</b> is defined as a group of participants randomly assigned to not receiving the active medication or factor under study and thereby serving as a comparison group for the intervention. <b>Placebo group</b> is defined as a group of women randomly assigned to receive a dummy treatment. </p> <p>Treatment for primary PPH requires a multidisciplinary approach. Any measures and/or drug therapy taken as part of the initial treatment is considered <b>first‐line therapy</b> . In most cases, this includes resuscitation measures, exclusion of genital tract laceration, checking of the placenta and the use of uterotonics. Women who continue to bleed require further assessment and interventions to control the bleeding, commonly referred to as <b>second‐line therapy</b>. This may include additional uterotonics, haemostatic drugs, surgical interventions, radiological embolisation and/or compression devices (<a href="./references#CD003249-bbs2-0027" title="Abou El SenounG , SinghM , MousaHA , AlfirevicZ . Update on the new modalities on the prevention and management of postpartum haemorrhage. Fetal and Maternal Medicine Review2011;22(4):247‐64. ">Abou El Senoun 2011</a>).  </p> </section> <section id="CD003249-sec-0053"> <h4 class="title">Types of outcome measures</h4> <section id="CD003249-sec-0054"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD003249-list-0005"> <li> <p>Maternal mortality.</p> </li> <li> <p>Serious maternal morbidity (renal or respiratory failure, cardiac arrest or multiple‐organ failure). </p> </li> <li> <p>Admission to intensive care.</p> </li> <li> <p>Hysterectomy (provided it is not part of the intervention under investigation).</p> </li> </ul> </p> </section> <section id="CD003249-sec-0055"> <h5 class="title">Secondary outcomes</h5> <section id="CD003249-sec-0056"> <h6 class="title">Outcome measures related to blood loss</h6> <p> <ul id="CD003249-list-0006"> <li> <p>Number of women with total blood loss 500 mL or more after enrolment.</p> </li> <li> <p>Number of women with total blood loss 1000 mL or more after enrolment.</p> </li> <li> <p>Mean blood loss (mL).</p> </li> <li> <p>Blood transfusion.</p> </li> <li> <p>Duration from randomisation to cessation of bleeding or obtaining satisfactory response (as determined by the trialist). </p> </li> <li> <p>Post‐randomisation additional uterotonic used to control bleeding.</p> </li> <li> <p>Post‐randomisation surgical intervention used to control bleeding.</p> </li> </ul> </p> </section> <section id="CD003249-sec-0057"> <h6 class="title">Side effects</h6> <p>Side effects of therapy or intervention (such as headache, vomiting, injuries). These will be related to the type of intervention under investigation. </p> </section> <section id="CD003249-sec-0058"> <h6 class="title">Other</h6> <p> <ul id="CD003249-list-0007"> <li> <p>Days in hospital.</p> </li> <li> <p>Iron therapy in the puerperium.</p> </li> <li> <p>Secondary PPH (vaginal bleeding after 24 hours to 42 days following delivery).</p> </li> <li> <p>Interventions to control secondary PPH (medical, surgical or both).</p> </li> <li> <p>Hospital readmission and number of days in hospital.</p> </li> <li> <p>Failure to continue breastfeeding at discharge from hospital and at 42 days of delivery.</p> </li> <li> <p>Economic outcomes.</p> </li> <li> <p>Maternal dissatisfaction with therapy.</p> </li> <li> <p>Quality of life, including physiological activity and social and emotional changes.</p> </li> </ul> </p> <p>Assessment of blood loss could vary between trials. It is expected that measurement of blood and blood clots in jars and weighing of linen are likely to be more precise than clinical judgement. The latter is known to underestimate blood loss (<a href="./references#CD003249-bbs2-0116" title="PritchardJA , BaldwinRM , DickeyJC , WigginsKM . Blood volume changes in pregnancy and puerperium, II: red blood cell loss and changes in apparent blood volume during and following vaginal delivery, cesarean section, and cesarean section plus total hysterectomy. American Journal of Obstetrics and Gynecology1962;84:1271‐82. ">Pritchard 1962</a>). The way of reporting the amount of loss as 'greater than' or 'greater than or equal to' a certain cutoff level (e.g. greater than 500 mL or greater than or equal to 500 mL) may affect the total reported amount of blood loss, especially when this amount is estimated. It is expected that trials evaluating uterotonic or haemostatic drugs may use other uterotonics to maintain contractions of the uterus after randomisation. Also, it should be taken into consideration that hysterectomy could be a method of intervention or co‐intervention, as well as an outcome measure. </p> </section> </section> </section> </section> <section id="CD003249-sec-0059"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003249-sec-0060"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register by contacting the Trials Search Co‐ordinator (31 August 2013). </p> <p>The Cochrane Pregnancy and Childbirth Group’s Trials Register is maintained by the Trials Search Co‐ordinator and contains trials identified from: </p> <p> <ol id="CD003249-list-0008"> <li> <p>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</p> </li> <li> <p>weekly searches of MEDLINE;</p> </li> <li> <p>weekly searches of Embase;</p> </li> <li> <p>handsearches of 30 journals and the proceedings of major conferences;</p> </li> <li> <p>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts. </p> </li> </ol> </p> <p>Details of the search strategies for CENTRAL, MEDLINE and Embase, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the ‘Specialized Register’ section within the editorial information about the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html" target="_blank">Cochrane Pregnancy and Childbirth Group</a>. </p> <p>Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co‐ordinator searches the register for each review using the topic list rather than keywords.¬ </p> <p>We did not apply any language restrictions.</p> </section> </section> <section id="CD003249-sec-0061"> <h3 class="title" id="CD003249-sec-0061">Data collection and analysis</h3> <p>For methods used in assessing the trials identified in the previous version of this review, see <a href="./references#CD003249-bbs2-0142" title="MousaHA , AlfirevicZ . Treatment for primary postpartum haemorrhage. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD003249.pub2] ">Mousa 2007</a>. </p> <p>For this update (2014), we used the following methods when assessing trials identified by the search. </p> <section id="CD003249-sec-0062"> <h4 class="title">Selection of studies</h4> <p>Two review authors (HAM and GAES or HAM and HS) independently assessed for inclusion all potential studies identified as a result of the search strategy. We resolved any disagreement through discussion and consultation with ZA. </p> </section> <section id="CD003249-sec-0063"> <h4 class="title">Data extraction and management</h4> <p>HAM designed a special data extraction form. For eligible studies, at least two review authors (HAM and GAES or HAM and HS) extracted data using the agreed form. We resolved any discrepancies through discussion and consultation with ZA. </p> <p>HAM and GAES entered data into Review Manager software (<a href="./references#CD003249-bbs2-0119" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>) and checked for accuracy. </p> <p>When information regarding any of the above was unclear, we attempted to contact authors of the original reports to provide further details. </p> <p>In addition to the main outcomes, we systematically extracted the following data for each study. </p> <p> <ul id="CD003249-list-0009"> <li> <p>Trial entry criteria (specific inclusion and exclusion criteria).</p> </li> <li> <p>Exclusions and missing data after randomisation.</p> </li> <li> <p>Mode of delivery.</p> </li> <li> <p>Management of the third stage of labour.</p> </li> <li> <p>Duration and technique of assessment of blood loss.</p> </li> </ul> </p> </section> <section id="CD003249-sec-0064"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>HAM and HS independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003249-bbs2-0078" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Any disagreement was resolved by discussion with ZA. </p> <section id="CD003249-sec-0065"> <h5 class="title">(1) Random sequence generation (checking for possible selection bias)</h5> <p>We have described for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. </p> <p>We have assessed the method as:</p> <p> <ul id="CD003249-list-0010"> <li> <p>low risk of bias (any truly random process, e.g. random number table; computer random number generator); </p> </li> <li> <p>high risk of bias (any non‐random process, e.g. odd or even date of birth; hospital or clinic record number); or </p> </li> <li> <p>unclear risk of bias.   </p> </li> </ul> </p> </section> <section id="CD003249-sec-0066"> <h5 class="title">(2) Allocation concealment (checking for possible selection bias)</h5> <p>We have described for each included study in sufficient detail the method used to conceal the allocation sequence and have determined whether intervention allocation could have been foreseen in advance of or during recruitment, or changed after assignment. </p> <p>We have assessed the methods as:</p> <p> <ul id="CD003249-list-0011"> <li> <p>low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); </p> </li> <li> <p>high risk of bias (open random allocation; unsealed or non‐opaque envelopes; alternation; date of birth); or </p> </li> <li> <p>unclear risk of bias.   </p> </li> </ul> </p> </section> <section id="CD003249-sec-0067"> <h5 class="title">(3.1) Blinding of participants and personnel (checking for possible performance bias)</h5> <p>We have described for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. Studies were judged at low risk of bias if they were blinded or if we judged that the lack of blinding could not have affected the results. Blinding was assessed separately for different outcomes or classes of outcomes. </p> <p>We have assessed the methods as:</p> <p> <ul id="CD003249-list-0012"> <li> <p>low, high or unclear risk of bias for participants; and</p> </li> <li> <p>low, high or unclear risk of bias for personnel.</p> </li> </ul> </p> </section> <section id="CD003249-sec-0068"> <h5 class="title">(3.2) Blinding of outcome assessment (checking for possible detection bias)</h5> <p>We have described for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We have assessed methods used to blind outcome assessment as:</p> <p> <ul id="CD003249-list-0013"> <li> <p>low, high or unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD003249-sec-0069"> <h5 class="title">(4) Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations) </h5> <p>We have described for each included study, and for each outcome or class of outcomes, the completeness of data, including attrition and exclusions from the analysis. We have stated whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with the total of randomly assigned participants), reasons for attrition or exclusion where reported and whether missing data were balanced across groups or were related to outcomes. We have contacted authors regarding published data and to request any missing outcome data that was included in our analysis. </p> <p>We have assessed methods as:</p> <p> <ul id="CD003249-list-0014"> <li> <p>low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups); </p> </li> <li> <p>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; ‘as treated’ analysis done with substantial departure of intervention received from that assigned at randomisation); or </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD003249-sec-0070"> <h5 class="title">(5) Selective reporting bias</h5> <p>We have described for each included study how we investigated the possibility of selective outcome reporting bias and what we have found. </p> <p>We have assessed the methods as:</p> <p> <ul id="CD003249-list-0015"> <li> <p>low risk of bias (when it was clear that all of the study’s pre‐specified outcomes and all expected outcomes of interest to the review have been reported); </p> </li> <li> <p>high risk of bias (when not all of the study’s pre‐specified outcomes have been reported; one or more reported primary outcomes were not pre‐specified; outcomes of interest were reported incompletely and so cannot be used; study failed to include results of a key outcome that would have been expected to have been reported); or </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD003249-sec-0071"> <h5 class="title">(6) Other sources of bias</h5> <p>We have described for each included study any important concerns that we have about other possible sources of bias. </p> <p>We have assessed whether each study was free of other problems that could put it at risk of bias. </p> <p> <ul id="CD003249-list-0016"> <li> <p>Low risk of other bias.</p> </li> <li> <p>High risk of other bias.</p> </li> <li> <p>Unclear whether there is risk of other bias.</p> </li> </ul> </p> </section> <section id="CD003249-sec-0072"> <h5 class="title">(7) Overall risk of bias</h5> <p>We have made explicit judgements about whether studies are at high risk of bias, according to the criteria given in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003249-bbs2-0078" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). With reference to the items listed above, we have assessed the likely magnitude and direction of the bias, and whether we consider it likely to impact the findings.  </p> </section> </section> <section id="CD003249-sec-0073"> <h4 class="title">Measures of treatment effect</h4> <section id="CD003249-sec-0074"> <h5 class="title">Dichotomous data</h5> <p>For dichotomous data, we presented the results as summary risk ratios with 95% confidence intervals.  </p> </section> <section id="CD003249-sec-0075"> <h5 class="title">Continuous data</h5> <p>For continuous data, we used the mean difference if outcomes were measured in the same way between trials. We used the standardised mean difference to combine trials that measured the same outcome but used different methods.   </p> </section> </section> <section id="CD003249-sec-0076"> <h4 class="title">Unit of analysis issues</h4> <section id="CD003249-sec-0077"> <h5 class="title">Cluster‐randomised trials</h5> <p>No cluster‐randomised trials were identified for inclusion. In the future, if eligible for inclusion, we will include cluster‐randomised trials in the analyses, along with individually randomised trials. We will adjust sample sizes using the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Section 16.3.4) based on an estimate of the intracluster correlation coefficient (ICC) derived from the trial (if possible), from a similar trial or from a study of a similar population. If we use ICCs from other sources, we will report this and will conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identify both cluster‐randomised trials and individually randomised trials, we plan to synthesise the relevant information. We will consider it reasonable<br/> to combine the results from both if little heterogeneity is evident between the study designs and if interaction between the effect of the intervention and the choice of randomisation unit is considered to be unlikely. </p> <p>We will also acknowledge heterogeneity in the randomisation unit and will perform a (sensitivity or subgroup) analysis to investigate the effects of the<br/> randomisation unit. </p> </section> <section id="CD003249-sec-0078"> <h5 class="title">Cross‐over trials</h5> <p>We considered cross‐over designs inappropriate for this review question.</p> </section> </section> <section id="CD003249-sec-0079"> <h4 class="title">Dealing with missing data</h4> <p>For included studies, levels of attrition were noted. The impact of including studies with high levels of missing data in the overall assessment of treatment effect was explored by using sensitivity analysis. </p> <p>For all outcomes, analyses were carried out, as far as possible, on an intention‐to‐treat basis (i.e. we have included in the analyses all participants randomly assigned to each group). The denominator for each outcome in each trial was the number randomly assigned minus any participants whose outcomes are known to be missing. </p> </section> <section id="CD003249-sec-0080"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity in each meta‐analysis using Tau², I² and Chi² statistics. We regarded heterogeneity as substantial if I² was greater than 30% and either Tau² was greater than zero or a low P value (less than 0.10) was obtained in the Chi² test for heterogeneity. </p> </section> <section id="CD003249-sec-0081"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess reporting biases if 10 or more studies were included in the meta‐analysis. In this update (2014), no meta‐analysis included 10 or more studies. In future updates, if more studies are included, we will investigate reporting biases (such as publication bias) using funnel plots. We will visually assess funnel plot asymmetry. </p> </section> <section id="CD003249-sec-0082"> <h4 class="title">Data synthesis</h4> <p>We have carried out statistical analysis using the Review Manager software (<a href="./references#CD003249-bbs2-0119" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>). We used fixed‐effect meta‐analysis for combining data in cases where it is reasonable to assume that studies are estimating the same underlying treatment effect, that is, when trials are examining the same intervention, and the trials’ populations and methods are judged sufficiently similar. If clinical heterogeneity is sufficient to expect that underlying treatment effects differ between trials, or if substantial statistical heterogeneity was detected, we used random‐effects meta‐analysis to produce an overall summary if an average treatment effect across trials was considered clinically meaningful. The random‐effects summary was to be treated as the average range of possible treatment effects, and we planned to discuss the clinical implications of treatment effects differing between trials. If the average treatment effect was not clinically meaningful, we did not combine trials. </p> <p>If we used random‐effects analyses, results were presented as the average treatment effect with 95% confidence intervals and estimates of Tau² and I². </p> </section> <section id="CD003249-sec-0083"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We have carried out subgroup analyses according to route of administration and dose of the drug used for misoprostol trials a priori, irrespective of heterogeneity. </p> <p>In future updates, with the addition of new trials, if we identify substantial heterogeneity, we plan to investigate it further using the following subgroup analyses. </p> <p> <ul id="CD003249-list-0017"> <li> <p>Mode of delivery (caesarean versus vaginal delivery).</p> </li> <li> <p>Setting (hospital versus community).</p> </li> </ul> </p> <p>All primary outcome measures will be used in subgroup analyses.</p> <p>We plan to assess subgroup differences by using interaction tests available within RevMan (<a href="./references#CD003249-bbs2-0119" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>). We will report the results of subgroup analyses by quoting the Chi² statistic and P value, as well as the interaction test I² value. </p> <p>In the presence of significant heterogeneity (I² &gt; 30%), we will use random‐effects.</p> </section> <section id="CD003249-sec-0084"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to carry out sensitivity analyses to explore the effect on trial quality as assessed by concealment of allocation, high attrition rates or both, with poor‐quality studies excluded from the analyses to assess whether this made any difference to the overall result. Poor quality was defined as studies at high risk of bias for allocation concealment and/or incomplete outcome data. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003249-sec-0085" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003249-sec-0085"></div> <section id="CD003249-sec-0086"> <h3 class="title">Description of studies</h3> <section id="CD003249-sec-0087"> <h4 class="title">Included studies</h4> <p>Ten randomised clinical trials (RCTs) with a total of 4060 participants fulfilled our inclusion criteria and were included in this review </p> <section id="CD003249-sec-0088"> <h5 class="title">Uterotonic trials</h5> <p>Eight uterotonic studies were identified and considered for inclusion in this review. Of these, one was excluded (<a href="./references#CD003249-bbs2-0017" title="TakagiS , YoshidaT , TogoY , TochigiH , AbeM , SakataH , et al. The effects of intramyometrial injection of prostaglandin F2alpha on severe post‐partum hemorrhage. Prostaglandins1976;12(4):565‐79. ">Takagi 1976</a>) because the trial included women with blood loss less than 500 mL and the trial report did not allow analysis based on treatment allocation ('intention to treat'). Seven misoprostol trials were included in the review. Four placebo‐controlled trials compared misoprostol (at doses of 600 to 1000 mcg) versus placebo (1881 participants) among women receiving conventional uterotonics for primary postpartum haemorrhage (PPH) treatment (<a href="./references#CD003249-bbs2-0004" title="HofmeyrGJ , FerreiraS , NikodemVC , MangesiL , SingataM , JaftaZ , et al. Misoprostol for treating postpartum haemorrhage: a randomized controlled trial [ISRCTN72263357]. BMC Pregnancy and Childbirth2004;4(1):16. MaholwanaB , HofmeyrGJ , NikodemC , FerreiraS , SingataM , MangesiL , et al. Misoprostol for treating postpartum haemorrhage. Presented at: 21st Conference on Priorities in Perinatal Care in South Africa. 2002 March 5‐8; Eastern Cape, South Africa. ">Hofmeyr 2004</a>; <a href="./references#CD003249-bbs2-0006" title="WalravenG , DamphaY , BittayeB , SoweM , HofmeyrJ . Misoprostol in the treatment of postpartum haemorrhage in addition to routine management: a placebo randomised control trial. BJOG: an international journal of obstetrics and gynaecology2004;111:1014‐7. ">Walraven 2004</a>; <a href="./references#CD003249-bbs2-0007" title="VillarJ . Misoprostol to treat postpartum hemorrhage (PPH): a randomized controlled trial (Argentina, Egypt, South Africa, Thailand and Viet Nam). Current Controlled Trials (www.controlled‐trials.com/mrct) (accessed 21 March 2006). WidmerM , BlumJ , HofmeyrGJ , CarroliG , Abdel‐AleemH , LumbiganonP , et al. Misoprostol as an adjunct to standard uterotonics for treatment of post‐partum haemorrhage: a multicentre, double‐blind randomised trial. Lancet2010;375(9728):1808‐13. ">Widmer 2010</a>; <a href="./references#CD003249-bbs2-0010" title="ZuberiNF , DurocherJ , SikanderR , BaberN , BlumJ , WalravenG . Misoprostol in addition to routine treatment of postpartum hemorrhage: a hospital‐based randomized‐controlled trial in Karachi, Pakistan. BMC Pregnancy and Childbirth2008;8:40. ">Zuberi 2008</a>). The main objective of these studies was to assess the effectiveness of the randomly selected drug to result in fewer women having additional blood loss of 500 mL of more. <a href="./references#CD003249-bbs2-0005" title="LokugamageAU , MoodleyJ , SullivanK , RodeckCH , NiculescuL , TigereP . The Durban primary postpartum haemorrhage study. Women's Health—into the new millennium. Proceedings of the 4th International Scientific Meeting of the Royal College of Obstetricians and Gynaecologists; 1999 October 3‐6; Cape Town, South Africa. 1999:77‐8. LokugamageAU , SullivanKR , NiculescuI , TigereP , OnyangungaF , ElRefaeyH , et al. A randomized study comparing rectally administered misoprostol versus syntometrine combined with an oxytocin infusion for the cessation of primary post partum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica2001;80(9):835‐9. ">Lokugamage 2001</a> (64 participants) compared rectally administered misoprostol (800 mcg) versus oxytocics (combined syntometrine and oxytocin infusion) for the treatment of primary PPH, defined as blood loss greater than 500 mL. The main objective of the study was to assess the effectiveness of the randomly selected drug to stop PPH within 20 minutes. The <a href="./references#CD003249-bbs2-0001" title="BlumJ , WinikoffB , RaghavanS , DabashR , RamadanMC , DilbazB , et al. Treatment of post‐partum haemorrhage with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin: a double‐blind, randomised, non‐inferiority trial. Lancet2010;375(9710):217‐23. BlumJ , WinikoffB , RaghavanS , DabashR , RamadanMC , DilbazB , et al. Treatment of postpartum hemorrhage with sublingual misoprostol versus oxytocin: results from a randomized noninferiority trial among women receiving prophylactic oxytocin. International Journal of Gynecology &amp; Obstetrics2009;107(Suppl 2):S22‐S23. DaoB , BlumJ , BarreraG , Cherine RamadanM , DabashR , DarwishE , et al. Side effect profiles for misoprostol and oxytocin in the treatment of postpartum hemorrhage. International Journal of Gynecology &amp; Obstetrics2009;107(Suppl 2):S150. ">Blum 2010</a> and <a href="./references#CD003249-bbs2-0008" title="WinikoffB . Misoprostol for the treatment of postpartum hemorrhage. ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 20 February 2008). WinikoffB , DabashR , DurocherJ , DarwishE , NgocNTN , LeonW , et al. Treatment of postpartum hemorrhage with sublingual misoprostol versus oxytocin: results from a randomized, non‐inferiority trial among women not exposed to oxytocin during labor. International Journal of Gynecology &amp; Obstetrics2009;107(Suppl 2):S59. WinikoffB , DabashR , DurocherJ , DarwishE , NguyenTN , LeonW , et al. Treatment of post‐partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double‐blind, randomised, non‐inferiority trial. Lancet2010;375(9710):210‐6. ">Winikoff 2010</a> trials (1787 participants) compared sublingual misoprostol (800 mcg) versus oxytocin infusion (40 IU infusion) for the treatment of primary PPH among women who had a vaginal delivery with clinically diagnosed or measured blood loss of 700 mL or more within the first hour of delivery. The main objective of these studies was to assess the effectiveness of the randomly selected drug to stop PPH within 20 minutes and/or to result in additional blood loss of at least 300 mL. The latter was restricted to women who had received prophylactic oxytocin during the second or third stage of labour. </p> </section> <section id="CD003249-sec-0089"> <h5 class="title">Haemostatic trials</h5> <p><a href="./references#CD003249-bbs2-0003" title="Ducloy‐BouthersA , BroisinF , KeitaH , FontaineS , DepretS , LegoeffF , et al. Tranexamic acid reduces blood loss in postpartum haemorrhage. Critical Care2010;14()(Suppl 1):S124. Ducloy‐BouthorsAS , DuhamelA , BroisinF , KeitaH , FontaineS . Tranexamic acid reduces blood loss in post‐partum haemorrhage by reducing hyperfibrinolysis. British Journal of Anaesthesia2012;108:ii191. Ducloy‐BouthorsAS , DuhamelA , TournoysA , Prado‐DupontA , DebizeG , PeneauE , et al. Post‐partum haemorrhage induced hyperfibrinolysis. Thrombosis Research2013;131(Suppl 1):S89‐90. Ducloy‐BouthorsAS , JudeB , DuhamelA , BroisinF , HuissoudC , Keita‐MeyerH , et al. High‐dose tranexamic acid reduces blood loss in postpartum haemorrhage. Critical Care (London, England)2011;15(2):R117. ">Ducloy‐Bouthors 2011</a> (144 participants) evaluated the place of intravenous tranexamic acid (loading dose 4 g intravenously over one hour, then infusion of 1 g/hour over six hours) among women with primary PPH, defined as measured blood loss of more than 800 mL, following vaginal delivery. All participants with PPH &gt; 500 mL were managed according to French practice guidelines: bladder catheter, manual removal of retained placenta, genital tract examination, uterine exploration and oxytocin (30 U/30 min), followed, and if these procedures were inefficacious, sulprostone was administered (500 μg in one hour) with no procoagulant treatment. Patients with PPH &gt; 800 mL were included in the study. Immediately after inclusion, participants were randomly assigned to receive tranexamic acid (tranexamic acid group) or no antifibrinolytic treatment (control group). The main objective of the study was to assess the effect of randomly assigned tranexamic acid administration on blood loss at 30 minutes, two hours and six hours of administration. </p> </section> <section id="CD003249-sec-0090"> <h5 class="title">Other drug therapy trials</h5> <p><a href="./references#CD003249-bbs2-0009" title="ZhouM , YangCY , ZhaoY , LiP . Clinical value of adjuvant therapy with estrogen for postpartum hemorrhage. Journal of Southern Medical University2006;26(6):865‐6. ">Zhou 2006</a> (112 participants) assessed the additional benefit of estrogen adjuvant therapy (4 mg estradiol benzoate injected intramuscularly) for the amount of blood loss at two and 24 hours among women with primary PPH. 4 mg estradiol benzoate injected intramuscularly with routine management when bleeding exceeded 500 mL versus routine management only for the control group. Routine management of the control group was described as 'uterine massage and uterotonics administration' and included '20 U cervical muscle injection to contract the uterus; 20 U intravenous drip to contract the uterus'. In case of the cervical muscles not restoring, injection or intravenous drip did not exceed 80 U. </p> </section> <section id="CD003249-sec-0091"> <h5 class="title">Surgical trials</h5> <p><a href="./references#CD003249-bbs2-0002" title="ChantrapitakW , SrijanteokK , Puangsa‐artS . Lower uterine segment compression for management of early postpartum hemorrhage after vaginal delivery at Charoenkrung Pracharak Hospital. Journal of the Medical Association of Thailand2009;92(5):600‐5. ">Chantrapitak 2009</a> (64 participants) assessed the amount of blood loss at two hours after randomly assigning women with primary PPH (defined as blood loss 500 mL or more) to lower uterine segment compression in addition to conventional therapy for primary PPH versus conventional therapy alone. </p> <p>We did not identify any trials related to uterine tamponade, uterine compression suturing techniques, artery ligations or radiological interventions. </p> <p>For further details of included studies, see table of <a href="./references#CD003249-sec-0131" title="">Characteristics of included studies</a>. </p> </section> </section> <section id="CD003249-sec-0092"> <h4 class="title">Excluded studies</h4> <p>For details of excluded studies, see table of <a href="./references#CD003249-sec-0132" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD003249-sec-0093"> <h3 class="title">Risk of bias in included studies</h3> <p>Please see <a href="#CD003249-fig-0001">Figure 1</a> and <a href="#CD003249-fig-0002">Figure 2</a> for summary of risk of bias assessments. </p> <div class="figure" id="CD003249-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003249-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD003249-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003249-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>The <a href="./references#CD003249-bbs2-0005" title="LokugamageAU , MoodleyJ , SullivanK , RodeckCH , NiculescuL , TigereP . The Durban primary postpartum haemorrhage study. Women's Health—into the new millennium. Proceedings of the 4th International Scientific Meeting of the Royal College of Obstetricians and Gynaecologists; 1999 October 3‐6; Cape Town, South Africa. 1999:77‐8. LokugamageAU , SullivanKR , NiculescuI , TigereP , OnyangungaF , ElRefaeyH , et al. A randomized study comparing rectally administered misoprostol versus syntometrine combined with an oxytocin infusion for the cessation of primary post partum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica2001;80(9):835‐9. ">Lokugamage 2001</a> trial compared misoprostol (800 mcg rectal) versus syntometrine combined with oxytocin infusion for treatment of PPH. The authors described clearly the random generation method and allocation concealment using consecutively numbered, sealed, opaque envelopes. It was a single‐blinded study, as obstetricians were aware of the type of drug given, although women and midwives were not. The trial authors indicated that single blinding was used mainly for safety "to prevent over‐dosage and to know what had been given in case of need of additional drugs". No description was provided of the method of measurement of blood loss or the management of the third stage of labour. The authors have been contacted to request more information. Post‐randomisation withdrawal of one woman (1/32) was reported in the misoprostol arm. The trial was prone to assessment bias, as physicians were aware of the treatment given. Generalisation of the results (external validity) is somewhat limited because effectiveness outcomes such as 'treatment failure' were susceptible to biased ascertainment. Furthermore, the authors performed an interim analysis after 12 months (30 recruited women), and it is unclear whether this information was shared with the clinicians participating in the trial. Therefore, one cannot rule out the possibility that postrandomisation management and outcome assessment were influenced by knowledge of interim results. The study was terminated after an interim analysis revealed an 80% difference between the two treatment arms for the pre‐specified outcome measure (effectiveness at stopping PPH within 20 minutes of trial drugs' administration). Only three outcome measures were adequately reported (hysterectomy, persistent vaginal bleeding following randomisation, medical and surgical co‐interventions). Maternal death was not reported as an outcome. Other reported outcome measures included blood transfusion, length of inpatient stay and drug side effects. However, they were reported as "P value of significance" with no numbers or percentages. No long‐term outcome data were presented. </p> <p>The <a href="./references#CD003249-bbs2-0006" title="WalravenG , DamphaY , BittayeB , SoweM , HofmeyrJ . Misoprostol in the treatment of postpartum haemorrhage in addition to routine management: a placebo randomised control trial. BJOG: an international journal of obstetrics and gynaecology2004;111:1014‐7. ">Walraven 2004</a> and <a href="./references#CD003249-bbs2-0004" title="HofmeyrGJ , FerreiraS , NikodemVC , MangesiL , SingataM , JaftaZ , et al. Misoprostol for treating postpartum haemorrhage: a randomized controlled trial [ISRCTN72263357]. BMC Pregnancy and Childbirth2004;4(1):16. MaholwanaB , HofmeyrGJ , NikodemC , FerreiraS , SingataM , MangesiL , et al. Misoprostol for treating postpartum haemorrhage. Presented at: 21st Conference on Priorities in Perinatal Care in South Africa. 2002 March 5‐8; Eastern Cape, South Africa. ">Hofmeyr 2004</a> trials were double‐blinded studies that compared misoprostol (600 mcg in Walraven and 1000 mcg in Hofmeyr, delivered by multiple routes) versus placebo when used as an adjunct to standard uterotonics for the treatment of primary PPH. However, the authors of the former trial believed that blinding may have been compromised by differences in the size of the misoprostol tablets and the placebo. Both trials used active management of the third stage of labour and measured blood loss after administration of conventional oxytocics for primary PPH treatment and the trial drug. In <a href="./references#CD003249-bbs2-0004" title="HofmeyrGJ , FerreiraS , NikodemVC , MangesiL , SingataM , JaftaZ , et al. Misoprostol for treating postpartum haemorrhage: a randomized controlled trial [ISRCTN72263357]. BMC Pregnancy and Childbirth2004;4(1):16. MaholwanaB , HofmeyrGJ , NikodemC , FerreiraS , SingataM , MangesiL , et al. Misoprostol for treating postpartum haemorrhage. Presented at: 21st Conference on Priorities in Perinatal Care in South Africa. 2002 March 5‐8; Eastern Cape, South Africa. ">Hofmeyr 2004</a>, six of 244 data sheets did not include pack numbers and could not be included in the analysis. In the <a href="./references#CD003249-bbs2-0006" title="WalravenG , DamphaY , BittayeB , SoweM , HofmeyrJ . Misoprostol in the treatment of postpartum haemorrhage in addition to routine management: a placebo randomised control trial. BJOG: an international journal of obstetrics and gynaecology2004;111:1014‐7. ">Walraven 2004</a> trial, no withdrawals after enrolment were reported. No long‐term outcome data were presented. </p> <p>The <a href="./references#CD003249-bbs2-0010" title="ZuberiNF , DurocherJ , SikanderR , BaberN , BlumJ , WalravenG . Misoprostol in addition to routine treatment of postpartum hemorrhage: a hospital‐based randomized‐controlled trial in Karachi, Pakistan. BMC Pregnancy and Childbirth2008;8:40. ">Zuberi 2008</a> trial was a multi‐centre double‐blind randomised controlled study that compared sublingual misoprostol (600 mcg) versus placebo when used as an adjunct to standard uterotonics for the treatment of primary PPH. Blinding and allocation concealment were adequate, and participants were randomly assigned in blocks of 10, using a computer‐generated random sequence. Placebo tablets were identical in shape, colour, weight, feel and taste to misoprostol tablets. The study was powered to recruit 900 participants; however, investigators managed to recruit only 61 participants and reported results for 59 of them. The primary outcome measure was measured blood loss of 500 mL or more after treatment. Authors indicated that accurate use of the scales for assessment of blood loss proved difficult. Therefore, volume of blood was not analysed; instead measurement according to reading of the blood collection device was recorded and analysed. No long‐term outcome data were presented. </p> <p>The <a href="./references#CD003249-bbs2-0007" title="VillarJ . Misoprostol to treat postpartum hemorrhage (PPH): a randomized controlled trial (Argentina, Egypt, South Africa, Thailand and Viet Nam). Current Controlled Trials (www.controlled‐trials.com/mrct) (accessed 21 March 2006). WidmerM , BlumJ , HofmeyrGJ , CarroliG , Abdel‐AleemH , LumbiganonP , et al. Misoprostol as an adjunct to standard uterotonics for treatment of post‐partum haemorrhage: a multicentre, double‐blind randomised trial. Lancet2010;375(9728):1808‐13. ">Widmer 2010</a> trial was a multicentre double‐blind randomised controlled study that compared sublingual misoprostol (600 mcg) versus placebo when used as an adjunct to standard uterotonics for the treatment of primary PPH. Investigators used computer‐generated randomisation sequence in blocks of six and eight, stratified by country. Overall, blinding and allocation concealment were adequate. Placebo tablets were identical in shape, colour, weight, feel and taste to misoprostol tablets. A total of 1422 women were recruited to the study, three women did not receive interventions and five women were lost to follow‐up at 90 minutes, as blood loss was not recorded. The study was powered to measure impact on blood loss. Methods of blood collection and measurement varied between centres. However, trial authors indicated that some of the methods used had been previously evaluated in the World Health Organization trial of misoprostol for the prevention of PPH (<a href="./references#CD003249-bbs2-0073" title="GülmezogluAM , VillarJ , NgocNT , PiaggioG , CarroliG , AdetoroL , et al. WHO multicentre randomised trial of misoprostol in the management of the third stage of labour. Lancet2001;358(9283):689‐95. ">Gülmezoglu 2001</a>). Both groups received standard uterotonics for the treatment of primary PPH. No long‐term outcome data were presented. </p> <p>The <a href="./references#CD003249-bbs2-0001" title="BlumJ , WinikoffB , RaghavanS , DabashR , RamadanMC , DilbazB , et al. Treatment of post‐partum haemorrhage with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin: a double‐blind, randomised, non‐inferiority trial. Lancet2010;375(9710):217‐23. BlumJ , WinikoffB , RaghavanS , DabashR , RamadanMC , DilbazB , et al. Treatment of postpartum hemorrhage with sublingual misoprostol versus oxytocin: results from a randomized noninferiority trial among women receiving prophylactic oxytocin. International Journal of Gynecology &amp; Obstetrics2009;107(Suppl 2):S22‐S23. DaoB , BlumJ , BarreraG , Cherine RamadanM , DabashR , DarwishE , et al. Side effect profiles for misoprostol and oxytocin in the treatment of postpartum hemorrhage. International Journal of Gynecology &amp; Obstetrics2009;107(Suppl 2):S150. ">Blum 2010</a> and <a href="./references#CD003249-bbs2-0008" title="WinikoffB . Misoprostol for the treatment of postpartum hemorrhage. ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 20 February 2008). WinikoffB , DabashR , DurocherJ , DarwishE , NgocNTN , LeonW , et al. Treatment of postpartum hemorrhage with sublingual misoprostol versus oxytocin: results from a randomized, non‐inferiority trial among women not exposed to oxytocin during labor. International Journal of Gynecology &amp; Obstetrics2009;107(Suppl 2):S59. WinikoffB , DabashR , DurocherJ , DarwishE , NguyenTN , LeonW , et al. Treatment of post‐partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double‐blind, randomised, non‐inferiority trial. Lancet2010;375(9710):210‐6. ">Winikoff 2010</a> trials were double‐blind randomised controlled trials that compared sublingual misoprostol (800 mcg) versus oxytocin infusion (40 IU in one 1000 mL of saline over 15 minutes). Both described clearly their methods of allocation concealment and blinding and used similar inclusion and exclusion criteria. Placebo tablets were identical in shape, colour, weight, feel and taste to misoprostol tablets. However, the latter trial included only participants for whom oxytocic drugs were not administered during the second and third stages of labour. They used cessation of active bleeding within 20 minutes after initial treatment and additional blood loss of 300 mL or more as primary end points and reported outcomes in 100% of cases. No long‐term outcome data were reported. </p> <p>The <a href="./references#CD003249-bbs2-0003" title="Ducloy‐BouthersA , BroisinF , KeitaH , FontaineS , DepretS , LegoeffF , et al. Tranexamic acid reduces blood loss in postpartum haemorrhage. Critical Care2010;14()(Suppl 1):S124. Ducloy‐BouthorsAS , DuhamelA , BroisinF , KeitaH , FontaineS . Tranexamic acid reduces blood loss in post‐partum haemorrhage by reducing hyperfibrinolysis. British Journal of Anaesthesia2012;108:ii191. Ducloy‐BouthorsAS , DuhamelA , TournoysA , Prado‐DupontA , DebizeG , PeneauE , et al. Post‐partum haemorrhage induced hyperfibrinolysis. Thrombosis Research2013;131(Suppl 1):S89‐90. Ducloy‐BouthorsAS , JudeB , DuhamelA , BroisinF , HuissoudC , Keita‐MeyerH , et al. High‐dose tranexamic acid reduces blood loss in postpartum haemorrhage. Critical Care (London, England)2011;15(2):R117. ">Ducloy‐Bouthors 2011</a> trial was an open‐label randomised, controlled study. It was liable to selection and performance bias. Partial blinding was achieved, as obstetricians, midwives and participants were not aware of interventions used. However, anaesthetists were aware of the intervention and were responsible for randomisation and administration of the trial drug. It is unclear how the allocated intervention was concealed, as intravenous infusion would be visible to all. Investigators recruited 152 participants, but one was excluded, as it was found later that she did not fulfil the inclusion criteria. Protocol violations were reported for seven women (five in the tranexamic acid group and two in the control group), and the analysis reported on 144 participants (72 participants in each group). The study was not powered to measure any of our primary outcome measures. Investigators reported few long‐term outcome data. </p> <p>The <a href="./references#CD003249-bbs2-0009" title="ZhouM , YangCY , ZhaoY , LiP . Clinical value of adjuvant therapy with estrogen for postpartum hemorrhage. Journal of Southern Medical University2006;26(6):865‐6. ">Zhou 2006</a> trial was a randomised controlled study in which women were randomly assigned to conventional therapy versus estrogen adjuvant therapy in addition to conventional therapy. No description of methods of randomisation and blinding was provided. The study was underpowered to measure any impact on primary outcome measures. Investigators reported impact of outcome on blood loss and hysterectomy. However, the method used for measurement of blood loss was not described. </p> <p>The <a href="./references#CD003249-bbs2-0002" title="ChantrapitakW , SrijanteokK , Puangsa‐artS . Lower uterine segment compression for management of early postpartum hemorrhage after vaginal delivery at Charoenkrung Pracharak Hospital. Journal of the Medical Association of Thailand2009;92(5):600‐5. ">Chantrapitak 2009</a> trial was a randomised controlled study in which women were randomly assigned to lower uterine segment compression in addition to conventional therapy or conventional therapy only. Authors were contacted to clarify randomisation, and they have indicated that it occurred through random generation using opaque concealed envelopes. However, the study is prone to concealment bias, as clinicians were aware of interventions used. The trial was underpowered to measure impact on primary outcome measures. </p> </section> <section id="CD003249-sec-0094"> <h3 class="title" id="CD003249-sec-0094">Effects of interventions</h3> <section id="CD003249-sec-0095"> <h4 class="title">Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics (four trials, comparison 1) </h4> <p>Sublingual misoprostol at a dose of 600 mcg was used by <a href="./references#CD003249-bbs2-0010" title="ZuberiNF , DurocherJ , SikanderR , BaberN , BlumJ , WalravenG . Misoprostol in addition to routine treatment of postpartum hemorrhage: a hospital‐based randomized‐controlled trial in Karachi, Pakistan. BMC Pregnancy and Childbirth2008;8:40. ">Zuberi 2008</a> and <a href="./references#CD003249-bbs2-0007" title="VillarJ . Misoprostol to treat postpartum hemorrhage (PPH): a randomized controlled trial (Argentina, Egypt, South Africa, Thailand and Viet Nam). Current Controlled Trials (www.controlled‐trials.com/mrct) (accessed 21 March 2006). WidmerM , BlumJ , HofmeyrGJ , CarroliG , Abdel‐AleemH , LumbiganonP , et al. Misoprostol as an adjunct to standard uterotonics for treatment of post‐partum haemorrhage: a multicentre, double‐blind randomised trial. Lancet2010;375(9728):1808‐13. ">Widmer 2010</a> (total of 1483 women), in addition to conventional uterotonics, among women treated for primary PPH. A total dose of 600 mcg (200 mcg oral and 400 mcg sublingual) misoprostol was used simultaneously in <a href="./references#CD003249-bbs2-0006" title="WalravenG , DamphaY , BittayeB , SoweM , HofmeyrJ . Misoprostol in the treatment of postpartum haemorrhage in addition to routine management: a placebo randomised control trial. BJOG: an international journal of obstetrics and gynaecology2004;111:1014‐7. ">Walraven 2004</a> (160 participants), and <a href="./references#CD003249-bbs2-0004" title="HofmeyrGJ , FerreiraS , NikodemVC , MangesiL , SingataM , JaftaZ , et al. Misoprostol for treating postpartum haemorrhage: a randomized controlled trial [ISRCTN72263357]. BMC Pregnancy and Childbirth2004;4(1):16. MaholwanaB , HofmeyrGJ , NikodemC , FerreiraS , SingataM , MangesiL , et al. Misoprostol for treating postpartum haemorrhage. Presented at: 21st Conference on Priorities in Perinatal Care in South Africa. 2002 March 5‐8; Eastern Cape, South Africa. ">Hofmeyr 2004</a> (238 participants) used 1000 mcg misoprostol simultaneously (200 mcg oral, 400 mcg sublingual and 400 mcg rectal). </p> <section id="CD003249-sec-0096"> <h5 class="title">Primary outcomes</h5> <p>Compared with placebo, misoprostol conferred no additional benefit in terms of reduction in the rate of maternal mortality (risk ratio (RR) 6.16, 95% confidence interval (CI) 0.75 to 50.85; 5/930 versus 0/951; <a href="./references#CD003249-fig-0003" title="">Analysis 1.1</a>) and hysterectomy (average RR 0.93, 95% CI 0.16 to 5.41; random‐effects, Tau² = 0.83, I² = 33%; 5/930 versus 5/951; <a href="./references#CD003249-fig-0006" title="">Analysis 1.4</a>). Only <a href="./references#CD003249-bbs2-0007" title="VillarJ . Misoprostol to treat postpartum hemorrhage (PPH): a randomized controlled trial (Argentina, Egypt, South Africa, Thailand and Viet Nam). Current Controlled Trials (www.controlled‐trials.com/mrct) (accessed 21 March 2006). WidmerM , BlumJ , HofmeyrGJ , CarroliG , Abdel‐AleemH , LumbiganonP , et al. Misoprostol as an adjunct to standard uterotonics for treatment of post‐partum haemorrhage: a multicentre, double‐blind randomised trial. Lancet2010;375(9728):1808‐13. ">Widmer 2010</a> and <a href="./references#CD003249-bbs2-0010" title="ZuberiNF , DurocherJ , SikanderR , BaberN , BlumJ , WalravenG . Misoprostol in addition to routine treatment of postpartum hemorrhage: a hospital‐based randomized‐controlled trial in Karachi, Pakistan. BMC Pregnancy and Childbirth2008;8:40. ">Zuberi 2008</a> reported serious maternal morbidity (RR 0.34, 95% CI 0.01 to 8.31; 0/734 versus 1/749; <a href="./references#CD003249-fig-0004" title="">Analysis 1.2</a>) and admission to the intensive care unit (RR 0.79, 95% CI 0.30 to 2.11; 7/734 versus 9/749; <a href="./references#CD003249-fig-0005" title="">Analysis 1.3</a>). </p> </section> <section id="CD003249-sec-0097"> <h5 class="title">Secondary outcomes</h5> <p>Compared with placebo, misoprostol administered in addition to conventional uterotonics had no significant impact on blood loss of at least 500 mL (RR 0.89, 95% CI 0.71 to 1.12; 121/930 versus 138/950; <a href="./references#CD003249-fig-0008" title="">Analysis 1.6</a>), blood loss of at least 1000 mL (RR 0.88, 95% CI 0.42 to 1.86; 12/930 versus 14/950; <a href="./references#CD003249-fig-0010" title="">Analysis 1.8</a>) or blood transfusion (RR 0.95, 95% CI 0.77 to 1.17; 139/928 versus 150/949; <a href="./references#CD003249-fig-0009" title="">Analysis 1.7</a>). </p> </section> <section id="CD003249-sec-0098"> <h5 class="title">Side effects</h5> <p>Compared with placebo, misoprostol intake by any route was associated with a significant increase in vomiting (RR 1.84, 95% CI 1.16 to 2.95; <a href="./references#CD003249-fig-0020" title="">Analysis 1.18</a>), shivering (average RR 2.25, 95% CI 1.76 to 2.88; heterogeneity: Tau² = 0.02; Chi² = 4.71, df = 3 (P = 0.19); I² = 36%; <a href="./references#CD003249-fig-0025" title="">Analysis 1.23</a>), maternal pyrexia of at least 38°C (RR 3.12, 95% CI 2.66 to 3.67; <a href="./references#CD003249-fig-0022" title="">Analysis 1.20</a>) and maternal pyrexia of 40°C or more (RR 13.58, 95% CI 4.93 to 37.44; <a href="./references#CD003249-fig-0023" title="">Analysis 1.21</a>). </p> </section> </section> <section id="CD003249-sec-0099"> <h4 class="title">Misoprostol versus other uterotonics given to women who have not received any conventional uterotonic therapy (three trials, comparisons 2 and 3) </h4> <p>Sublingual misoprostol (800 mcg) was compared with oxytocin infusion (40 IU) in two trials (<a href="./references#CD003249-bbs2-0001" title="BlumJ , WinikoffB , RaghavanS , DabashR , RamadanMC , DilbazB , et al. Treatment of post‐partum haemorrhage with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin: a double‐blind, randomised, non‐inferiority trial. Lancet2010;375(9710):217‐23. BlumJ , WinikoffB , RaghavanS , DabashR , RamadanMC , DilbazB , et al. Treatment of postpartum hemorrhage with sublingual misoprostol versus oxytocin: results from a randomized noninferiority trial among women receiving prophylactic oxytocin. International Journal of Gynecology &amp; Obstetrics2009;107(Suppl 2):S22‐S23. DaoB , BlumJ , BarreraG , Cherine RamadanM , DabashR , DarwishE , et al. Side effect profiles for misoprostol and oxytocin in the treatment of postpartum hemorrhage. International Journal of Gynecology &amp; Obstetrics2009;107(Suppl 2):S150. ">Blum 2010</a>; <a href="./references#CD003249-bbs2-0008" title="WinikoffB . Misoprostol for the treatment of postpartum hemorrhage. ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 20 February 2008). WinikoffB , DabashR , DurocherJ , DarwishE , NgocNTN , LeonW , et al. Treatment of postpartum hemorrhage with sublingual misoprostol versus oxytocin: results from a randomized, non‐inferiority trial among women not exposed to oxytocin during labor. International Journal of Gynecology &amp; Obstetrics2009;107(Suppl 2):S59. WinikoffB , DabashR , DurocherJ , DarwishE , NguyenTN , LeonW , et al. Treatment of post‐partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double‐blind, randomised, non‐inferiority trial. Lancet2010;375(9710):210‐6. ">Winikoff 2010</a>; 1787 women total). The latter was restricted to women who had received prophylactic oxytocin during the second or third stage of labour. </p> <p><a href="./references#CD003249-bbs2-0005" title="LokugamageAU , MoodleyJ , SullivanK , RodeckCH , NiculescuL , TigereP . The Durban primary postpartum haemorrhage study. Women's Health—into the new millennium. Proceedings of the 4th International Scientific Meeting of the Royal College of Obstetricians and Gynaecologists; 1999 October 3‐6; Cape Town, South Africa. 1999:77‐8. LokugamageAU , SullivanKR , NiculescuI , TigereP , OnyangungaF , ElRefaeyH , et al. A randomized study comparing rectally administered misoprostol versus syntometrine combined with an oxytocin infusion for the cessation of primary post partum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica2001;80(9):835‐9. ">Lokugamage 2001</a> compared rectal misoprostol (800 mcg) with a combination of oxytocin infusion and syntometrine (64 women). </p> <section id="CD003249-sec-0100"> <h5 class="title">Primary outcomes</h5> <p>In the <a href="./references#CD003249-bbs2-0001" title="BlumJ , WinikoffB , RaghavanS , DabashR , RamadanMC , DilbazB , et al. Treatment of post‐partum haemorrhage with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin: a double‐blind, randomised, non‐inferiority trial. Lancet2010;375(9710):217‐23. BlumJ , WinikoffB , RaghavanS , DabashR , RamadanMC , DilbazB , et al. Treatment of postpartum hemorrhage with sublingual misoprostol versus oxytocin: results from a randomized noninferiority trial among women receiving prophylactic oxytocin. International Journal of Gynecology &amp; Obstetrics2009;107(Suppl 2):S22‐S23. DaoB , BlumJ , BarreraG , Cherine RamadanM , DabashR , DarwishE , et al. Side effect profiles for misoprostol and oxytocin in the treatment of postpartum hemorrhage. International Journal of Gynecology &amp; Obstetrics2009;107(Suppl 2):S150. ">Blum 2010</a> and <a href="./references#CD003249-bbs2-0008" title="WinikoffB . Misoprostol for the treatment of postpartum hemorrhage. ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 20 February 2008). WinikoffB , DabashR , DurocherJ , DarwishE , NgocNTN , LeonW , et al. Treatment of postpartum hemorrhage with sublingual misoprostol versus oxytocin: results from a randomized, non‐inferiority trial among women not exposed to oxytocin during labor. International Journal of Gynecology &amp; Obstetrics2009;107(Suppl 2):S59. WinikoffB , DabashR , DurocherJ , DarwishE , NguyenTN , LeonW , et al. Treatment of post‐partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double‐blind, randomised, non‐inferiority trial. Lancet2010;375(9710):210‐6. ">Winikoff 2010</a> trials, no significant differences were noted between the two groups for any of the primary outcomes: maternal mortality (RR 0.99, 95% CI 0.06 to 15.74; <a href="./references#CD003249-fig-0028" title="">Analysis 2.1</a>), hysterectomy (RR 1.98, 95% CI 0.36 to 10.72; 4/895 versus 2/892; <a href="./references#CD003249-fig-0031" title="">Analysis 2.4</a>), admission to intensive care unit (RR 0.33, 95% CI 0.01 to 8.06; 0/895 versus 1/892; <a href="./references#CD003249-fig-0030" title="">Analysis 2.3</a>) and serious maternal morbidity (RR 0.33, 95% CI 0.01 to 8.06; 0/895 versus 1/892; <a href="./references#CD003249-fig-0029" title="">Analysis 2.2</a>).  </p> <p>In <a href="./references#CD003249-bbs2-0005" title="LokugamageAU , MoodleyJ , SullivanK , RodeckCH , NiculescuL , TigereP . The Durban primary postpartum haemorrhage study. Women's Health—into the new millennium. Proceedings of the 4th International Scientific Meeting of the Royal College of Obstetricians and Gynaecologists; 1999 October 3‐6; Cape Town, South Africa. 1999:77‐8. LokugamageAU , SullivanKR , NiculescuI , TigereP , OnyangungaF , ElRefaeyH , et al. A randomized study comparing rectally administered misoprostol versus syntometrine combined with an oxytocin infusion for the cessation of primary post partum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica2001;80(9):835‐9. ">Lokugamage 2001</a>, the rate of hysterectomy did not differ between the two groups (RR 0.33, 95% CI 0.01, 7.89; 0/32 versus 1/32; <a href="./references#CD003249-fig-0056" title="">Analysis 3.1</a>). However, the authors did not report rates of maternal morbidity, mortality or admission to the intensive care unit. </p> </section> <section id="CD003249-sec-0101"> <h5 class="title">Secondary outcome measures</h5> <p>Compared with oxytocin infusion, sublingual misoprostol use was associated with a significant increase in the number of women who had blood loss of at least 1000 mL (RR 2.65, 95% CI 1.04 to 6.75; <a href="./references#CD003249-fig-0034" title="">Analysis 2.7</a>) and blood transfusion (RR 1.47, 95% CI 1.02 to 2.14; <a href="./references#CD003249-fig-0035" title="">Analysis 2.8</a>). However, no significant differences were associated with blood loss of at least 500 mL (average RR 1.51, 95% CI 01.14 to 2.00; heterogeneity: Chi² = 8.54, df = 1 (P = 0.003); I² = 88%; <a href="./references#CD003249-fig-0032" title="">Analysis 2.5</a>) and postrandomisation use of additional uterotonics to control bleeding (average RR 1.30, 95% CI 0.57 to 2.94; random‐effects, Tau² = 0.30, I² = 88%; <a href="./references#CD003249-fig-0037" title="">Analysis 2.10</a>, analysed using a random‐effects model because of substantial heterogeneity). No significant differences were noted between the two groups regarding the number of women who required examination under anaesthesia, bimanual compression or surgical intervention to control bleeding.   </p> <p>The <a href="./references#CD003249-bbs2-0005" title="LokugamageAU , MoodleyJ , SullivanK , RodeckCH , NiculescuL , TigereP . The Durban primary postpartum haemorrhage study. Women's Health—into the new millennium. Proceedings of the 4th International Scientific Meeting of the Royal College of Obstetricians and Gynaecologists; 1999 October 3‐6; Cape Town, South Africa. 1999:77‐8. LokugamageAU , SullivanKR , NiculescuI , TigereP , OnyangungaF , ElRefaeyH , et al. A randomized study comparing rectally administered misoprostol versus syntometrine combined with an oxytocin infusion for the cessation of primary post partum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica2001;80(9):835‐9. ">Lokugamage 2001</a> trial found that rectal misoprostol (800 mcg) was more effective than combined oxytocin and syntometrine in decreasing the need for additional uterotonics (RR 0.18, 95% CI 0.04, 0.76; <a href="./references#CD003249-fig-0058" title="">Analysis 3.3</a>). No significant differences in any other pre‐specified secondary outcomes were reported. </p> </section> <section id="CD003249-sec-0102"> <h5 class="title">Side effects</h5> <p>Sublingual misoprostol use in 800 mcg was consistently associated with significantly higher rates of prostaglandin‐related side effects such as vomiting and shivering. </p> </section> </section> <section id="CD003249-sec-0103"> <h4 class="title">Estrogen adjuvant therapy trials (one trial, comparison 4)</h4> <p>Estrogen therapy (4 mg estradiol benzoate injected intramuscularly) in addition to conventional PPH treatment was evaluated in one single‐centre trial (<a href="./references#CD003249-bbs2-0009" title="ZhouM , YangCY , ZhaoY , LiP . Clinical value of adjuvant therapy with estrogen for postpartum hemorrhage. Journal of Southern Medical University2006;26(6):865‐6. ">Zhou 2006</a>, 112 women). 4 mg estradiol benzoate was injected intramuscularly when routine management was ineffective and bleeding exceeded 500 mL versus routine management only. Management of the control group was described as 'uterine massage and uterotonics administration' and included '20 U cervical muscle injection to contract the uterus; 20 U intravenous drip to contract the uterus. In case of the cervical muscles not restoring, injection or intravenous drip did not exceed 80 U. Where rate of blood loss exceeded 2000 mL, hysterectomy was performed'. </p> <section id="CD003249-sec-0104"> <h5 class="title">Primary outcomes</h5> <p>Three women in the control group and no women in the estrogen group required hysterectomy (RR 0.16, 95% CI 0.01 to 3.11; <a href="./references#CD003249-fig-0060" title="">Analysis 4.1</a>). </p> </section> <section id="CD003249-sec-0105"> <h5 class="title">Secondary outcomes</h5> <p>We have included two additional measures to assess blood loss, as authors did not report any of our pre‐specified secondary outcome measures. The authors reported a significant reduction in blood loss within two hours (‐274.90 mL mean difference (MD), 95% CI ‐384.72 to ‐165.08 mL; <a href="./references#CD003249-fig-0061" title="">Analysis 4.2</a>) and between two and 24 hours from intervention (‐50.70 mL MD, 95% CI ‐83.07 to ‐18.33 mL; <a href="./references#CD003249-fig-0062" title="">Analysis 4.3</a>). </p> </section> </section> <section id="CD003249-sec-0106"> <h4 class="title">Tranexamic acid (one trial, comparison 5)</h4> <p><a href="./references#CD003249-bbs2-0003" title="Ducloy‐BouthersA , BroisinF , KeitaH , FontaineS , DepretS , LegoeffF , et al. Tranexamic acid reduces blood loss in postpartum haemorrhage. Critical Care2010;14()(Suppl 1):S124. Ducloy‐BouthorsAS , DuhamelA , BroisinF , KeitaH , FontaineS . Tranexamic acid reduces blood loss in post‐partum haemorrhage by reducing hyperfibrinolysis. British Journal of Anaesthesia2012;108:ii191. Ducloy‐BouthorsAS , DuhamelA , TournoysA , Prado‐DupontA , DebizeG , PeneauE , et al. Post‐partum haemorrhage induced hyperfibrinolysis. Thrombosis Research2013;131(Suppl 1):S89‐90. Ducloy‐BouthorsAS , JudeB , DuhamelA , BroisinF , HuissoudC , Keita‐MeyerH , et al. High‐dose tranexamic acid reduces blood loss in postpartum haemorrhage. Critical Care (London, England)2011;15(2):R117. ">Ducloy‐Bouthors 2011</a> is the only placebo‐controlled trial of tranexamic acid (144 women). </p> <section id="CD003249-sec-0107"> <h5 class="title">Primary outcomes</h5> <p>No maternal deaths were reported in the study population. No significant difference was noted between the two groups regarding serious maternal morbidity (RR 0.33, 95% CI 0.01 to 8.05; 0/72 versus 1/72; <a href="./references#CD003249-fig-0064" title="">Analysis 5.2</a>), admission to the intensive care unit (RR 0.60, 95% CI 0.15 to 2.42; 3/72 versus 5/72; <a href="./references#CD003249-fig-0065" title="">Analysis 5.3</a>) and hysterectomy (RR 0.33, 95% CI 0.01 to 8.05; 0/72 versus 1/72; <a href="./references#CD003249-fig-0066" title="">Analysis 5.4</a>). </p> </section> <section id="CD003249-sec-0108"> <h5 class="title">Secondary outcomes</h5> <p>No significant differences were observed in any of the pre‐specified secondary outcome measures between women with primary PPH treated with tranexamic acid and those given placebo. </p> </section> <section id="CD003249-sec-0109"> <h5 class="title">Side effects</h5> <p>Nausea was common with tranexamic acid administration (RR 11.00, 95% CI 1.46 to 82.99; <a href="./references#CD003249-fig-0080" title="">Analysis 5.18</a>). Three cases of deep vein thrombosis were reported in the study population (two in the tranexamic acid group and one in the control group; RR 2.00, 95% CI 0.19 to 21.57; <a href="./references#CD003249-fig-0083" title="">Analysis 5.21</a>). </p> </section> </section> <section id="CD003249-sec-0110"> <h4 class="title">Lower uterine segment compression versus no compression (one trial, comparison 6)</h4> <p><a href="./references#CD003249-bbs2-0002" title="ChantrapitakW , SrijanteokK , Puangsa‐artS . Lower uterine segment compression for management of early postpartum hemorrhage after vaginal delivery at Charoenkrung Pracharak Hospital. Journal of the Medical Association of Thailand2009;92(5):600‐5. ">Chantrapitak 2009</a> compared lower uterine segment compression versus no intervention (64 women). </p> <section id="CD003249-sec-0111"> <h5 class="title">Primary outcomes</h5> <p>No maternal death, admission to the intensive care unit, serious maternal morbidity or hysterectomy was reported in the two groups. </p> </section> <section id="CD003249-sec-0112"> <h5 class="title">Secondary outcomes</h5> <p>The number of women who had blood loss of at least 500 mL was significantly lower among women who had lower segment compression (RR 0.13, 95% CI 0.02 to 0.94; <a href="./references#CD003249-fig-0095" title="">Analysis 6.4</a>). However, no difference was observed between the two groups regarding mean blood loss (‐105.00 mL MD, 95% CI ‐262.00 to 52 mL; <a href="./references#CD003249-fig-0097" title="">Analysis 6.6</a>), rate of blood transfusion (RR 2.33, 95% CI 0.66 to 8.23; <a href="./references#CD003249-fig-0098" title="">Analysis 6.7)</a>, number of women with blood loss of at least 1000 mL (RR 0.20, 95% CI 0.01 to 4.01; <a href="./references#CD003249-fig-0096" title="">Analysis 6.5</a>) and number who required surgical co‐intervention to control the bleeding (no events in either group, so not estimable) (<a href="./references#CD003249-fig-0099" title="">Analysis 6.8</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003249-sec-0113" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003249-sec-0113"></div> <section id="CD003249-sec-0114"> <h3 class="title" id="CD003249-sec-0114">Summary of main results</h3> <p>The current review evaluated 10 clinical trials that fulfilled our inclusion criteria. None was adequately powered to address our primary outcome measures. Seven uterotonics trials evaluated the use of misoprostol for the treatment of primary PPH. Data from this review show that when misoprostol was compared with placebo (four clinical trials), intravenous oxytocin (two trials) or combined oxytocin and ergometrine (one trial), no statistically significant differences were seen in clinically important outcomes including maternal mortality, serious maternal morbidity, admission to intensive care and hysterectomy. Secondary outcomes, such as blood loss greater than 1000 mL and use of additional uterotonics, favoured intravenous oxytocin over misoprostol. The review suggests that conventional primary PPH treatment with intravenous oxytocin should be recommended as the more effective treatment. </p> <p>The occurrence of five maternal deaths in the group of studies comparing misoprostol versus placebo is unexpected (5/930 versus 0/930; RR 6.16; 95% CI 0.75 to 50.85). This prompted Hofmeyr and colleagues to examine the frequency of maternal deaths among 40,000 participants in 46 clinical trials of misoprostol used for the prevention or treatment of PPH (<a href="./references#CD003249-bbs2-0140" title="HofmeyrGJ , GülmezogluAM , NovikovaN , LinderV , FerreiraS , PiaggioG . Misoprostol to prevent and treat postpartum haemorrhage: a systematic review and meta‐analysis of maternal deaths and dose‐related effects. Bulletin of the World Health Organization2009;87(9):666‐77. ">Hofmeyr 2009</a>). Of 11 maternal deaths reported in five clinical trials, eight occurred in women receiving misoprostol (odds ratio 2.49, 95% CI 0.67 to 8.13; <a href="./references#CD003249-bbs2-0140" title="HofmeyrGJ , GülmezogluAM , NovikovaN , LinderV , FerreiraS , PiaggioG . Misoprostol to prevent and treat postpartum haemorrhage: a systematic review and meta‐analysis of maternal deaths and dose‐related effects. Bulletin of the World Health Organization2009;87(9):666‐77. ">Hofmeyr 2009</a>). Subsequent trials comparing sublingual misoprostol versus intravenous oxytocin for treatment of primary PPH (<a href="./references#CD003249-bbs2-0001" title="BlumJ , WinikoffB , RaghavanS , DabashR , RamadanMC , DilbazB , et al. Treatment of post‐partum haemorrhage with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin: a double‐blind, randomised, non‐inferiority trial. Lancet2010;375(9710):217‐23. BlumJ , WinikoffB , RaghavanS , DabashR , RamadanMC , DilbazB , et al. Treatment of postpartum hemorrhage with sublingual misoprostol versus oxytocin: results from a randomized noninferiority trial among women receiving prophylactic oxytocin. International Journal of Gynecology &amp; Obstetrics2009;107(Suppl 2):S22‐S23. DaoB , BlumJ , BarreraG , Cherine RamadanM , DabashR , DarwishE , et al. Side effect profiles for misoprostol and oxytocin in the treatment of postpartum hemorrhage. International Journal of Gynecology &amp; Obstetrics2009;107(Suppl 2):S150. ">Blum 2010</a>; <a href="./references#CD003249-bbs2-0008" title="WinikoffB . Misoprostol for the treatment of postpartum hemorrhage. ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 20 February 2008). WinikoffB , DabashR , DurocherJ , DarwishE , NgocNTN , LeonW , et al. Treatment of postpartum hemorrhage with sublingual misoprostol versus oxytocin: results from a randomized, non‐inferiority trial among women not exposed to oxytocin during labor. International Journal of Gynecology &amp; Obstetrics2009;107(Suppl 2):S59. WinikoffB , DabashR , DurocherJ , DarwishE , NguyenTN , LeonW , et al. Treatment of post‐partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double‐blind, randomised, non‐inferiority trial. Lancet2010;375(9710):210‐6. ">Winikoff 2010</a>) have been more reassuring, with one maternal death reported in each group (1/895 versus 1/895; RR 0.99, 95% CI 0.06 to 15.74). Furthermore, another recent randomised trial comparing misoprostol versus placebo for PPH prevention reported no maternal deaths (<a href="./references#CD003249-bbs2-0094" title="MobeenN , DurocherJ , ZuberiN , JahanN , BlumJ , WasimS , et al. Administration of misoprostol by trained traditional birth attendants to prevent postpartum haemorrhage in homebirths in Pakistan: a randomised placebo‐controlled trial. BJOG: an international journal of obstetrics and gynaecology2011;118:353–61. ">Mobeen 2011</a>). </p> <p>Tranexamic acid has been used for the prevention of haemorrhage for quite some time (<a href="./references#CD003249-bbs2-0055" title="CRASH‐2 trial collaborators, ShakurH , RobertsI , BautistaR , CaballeroJ , CoatsT , et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH‐2): a randomised, placebo‐controlled trial. Lancet2010;376(9734):23‐32. ">CRASH‐2 trial collaborators 2010</a>; <a href="./references#CD003249-bbs2-0067" title="FerrerP , RobertsI , SydenhamE , BlackhallK , ShakurH . Anti‐fibrinolytic agents in post partum haemorrhage: a systematic review. BMC Pregnancy Childbirth2009;15(9):29. ">Ferrer 2009</a>; <a href="./references#CD003249-bbs2-0101" title="NovikovaN , HofmeyrGJ . Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD007872] ">Novikova 2010</a>; <a href="./references#CD003249-bbs2-0110" title="PeitsidisP , KadirRA . Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. Expert Opinion on Pharmacotherapy2011;12(4):503‐16. ">Peitsidis 2011</a>), but <a href="./references#CD003249-bbs2-0003" title="Ducloy‐BouthersA , BroisinF , KeitaH , FontaineS , DepretS , LegoeffF , et al. Tranexamic acid reduces blood loss in postpartum haemorrhage. Critical Care2010;14()(Suppl 1):S124. Ducloy‐BouthorsAS , DuhamelA , BroisinF , KeitaH , FontaineS . Tranexamic acid reduces blood loss in post‐partum haemorrhage by reducing hyperfibrinolysis. British Journal of Anaesthesia2012;108:ii191. Ducloy‐BouthorsAS , DuhamelA , TournoysA , Prado‐DupontA , DebizeG , PeneauE , et al. Post‐partum haemorrhage induced hyperfibrinolysis. Thrombosis Research2013;131(Suppl 1):S89‐90. Ducloy‐BouthorsAS , JudeB , DuhamelA , BroisinF , HuissoudC , Keita‐MeyerH , et al. High‐dose tranexamic acid reduces blood loss in postpartum haemorrhage. Critical Care (London, England)2011;15(2):R117. ">Ducloy‐Bouthors 2011</a> was the first published randomised trial that examined the use of tranexamic acid to treat primary PPH. The study is underpowered to assess any impact on pre‐specified primary outcome measures. The <a href="./references#CD003249-bbs2-0009" title="ZhouM , YangCY , ZhaoY , LiP . Clinical value of adjuvant therapy with estrogen for postpartum hemorrhage. Journal of Southern Medical University2006;26(6):865‐6. ">Zhou 2006</a> trial of estrogen adjuvant therapy was not big enough to evaluate the impact on primary and secondary outcomes. In the absence of any pharmacological studies to support this current approach, it is sensible to avoid any estrogen therapy for PPH, especially as risk of deep vein thrombosis is increased in the immediate postpartum period. </p> <p><a href="./references#CD003249-bbs2-0002" title="ChantrapitakW , SrijanteokK , Puangsa‐artS . Lower uterine segment compression for management of early postpartum hemorrhage after vaginal delivery at Charoenkrung Pracharak Hospital. Journal of the Medical Association of Thailand2009;92(5):600‐5. ">Chantrapitak 2009</a> described two new techniques to control blood loss through transabdominal compression of the lower uterine segment. These techniques appear simple and safe, do not require special skills and have no major side effects. Unfortunately, the authors did not specify which technique they used during the trial period. Lower uterine segment compression was associated with a modest reduction in mean blood loss and blood loss of at least 500 mL. The method warrants further evaluation, as it could be of considerable benefit in the management of women who develop primary PPH following home birth and require hospital transfer for further management. </p> <p>We focused on four parameters to evaluate the impact of PPH treatments on postrandomisation blood loss: (1) blood loss of at least 500 mL; (2) blood loss of at least 1000 mL; (3) blood transfusion and (4) mean blood loss after enrolment. In this regard, misoprostol provided no additional benefit when compared with placebo when given to women simultaneously treated with conventional uterotonics. Misoprostol was evaluated as an effective and easy to administer alternative to intravenous oxytocin as first‐line therapy for the treatment of primary PPH in two other trials (<a href="./references#CD003249-bbs2-0001" title="BlumJ , WinikoffB , RaghavanS , DabashR , RamadanMC , DilbazB , et al. Treatment of post‐partum haemorrhage with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin: a double‐blind, randomised, non‐inferiority trial. Lancet2010;375(9710):217‐23. BlumJ , WinikoffB , RaghavanS , DabashR , RamadanMC , DilbazB , et al. Treatment of postpartum hemorrhage with sublingual misoprostol versus oxytocin: results from a randomized noninferiority trial among women receiving prophylactic oxytocin. International Journal of Gynecology &amp; Obstetrics2009;107(Suppl 2):S22‐S23. DaoB , BlumJ , BarreraG , Cherine RamadanM , DabashR , DarwishE , et al. Side effect profiles for misoprostol and oxytocin in the treatment of postpartum hemorrhage. International Journal of Gynecology &amp; Obstetrics2009;107(Suppl 2):S150. ">Blum 2010</a>; <a href="./references#CD003249-bbs2-0008" title="WinikoffB . Misoprostol for the treatment of postpartum hemorrhage. ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 20 February 2008). WinikoffB , DabashR , DurocherJ , DarwishE , NgocNTN , LeonW , et al. Treatment of postpartum hemorrhage with sublingual misoprostol versus oxytocin: results from a randomized, non‐inferiority trial among women not exposed to oxytocin during labor. International Journal of Gynecology &amp; Obstetrics2009;107(Suppl 2):S59. WinikoffB , DabashR , DurocherJ , DarwishE , NguyenTN , LeonW , et al. Treatment of post‐partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double‐blind, randomised, non‐inferiority trial. Lancet2010;375(9710):210‐6. ">Winikoff 2010</a>). Compared with 40 IU oxytocin infusion, 800 mcg sublingual misoprostol was associated with a significant increase in the number of women who had blood loss of at least 1000 mL (RR 2.65, 95% CI 1.04 to 6.75), blood transfusion (RR 1.47, 95% CI 1.02 to 2.14) and mean blood loss (mL) (MD 44.86, 95% CI 26.50, 63.22). Therefore, where available, oxytocin infusion should be recommended as first‐line treatment for primary PPH. Lack of significant differences in primary outcomes suggests that, when oxytocin infusion is not available, sublingual misoprostol may serve as a valid alternative for providers seeking a uterotonic therapy for their patients. No significant difference was reported between tranexamic acid and placebo in the <a href="./references#CD003249-bbs2-0003" title="Ducloy‐BouthersA , BroisinF , KeitaH , FontaineS , DepretS , LegoeffF , et al. Tranexamic acid reduces blood loss in postpartum haemorrhage. Critical Care2010;14()(Suppl 1):S124. Ducloy‐BouthorsAS , DuhamelA , BroisinF , KeitaH , FontaineS . Tranexamic acid reduces blood loss in post‐partum haemorrhage by reducing hyperfibrinolysis. British Journal of Anaesthesia2012;108:ii191. Ducloy‐BouthorsAS , DuhamelA , TournoysA , Prado‐DupontA , DebizeG , PeneauE , et al. Post‐partum haemorrhage induced hyperfibrinolysis. Thrombosis Research2013;131(Suppl 1):S89‐90. Ducloy‐BouthorsAS , JudeB , DuhamelA , BroisinF , HuissoudC , Keita‐MeyerH , et al. High‐dose tranexamic acid reduces blood loss in postpartum haemorrhage. Critical Care (London, England)2011;15(2):R117. ">Ducloy‐Bouthors 2011</a> study in terms of women who had blood loss of at least 500 mL or at least 1000 mL. This is consistent with the results of two systematic reviews (<a href="./references#CD003249-bbs2-0067" title="FerrerP , RobertsI , SydenhamE , BlackhallK , ShakurH . Anti‐fibrinolytic agents in post partum haemorrhage: a systematic review. BMC Pregnancy Childbirth2009;15(9):29. ">Ferrer 2009</a>; <a href="./references#CD003249-bbs2-0101" title="NovikovaN , HofmeyrGJ . Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD007872] ">Novikova 2010</a>) that evaluated the use of tranexamic acid for the prevention of PPH. </p> </section> <section id="CD003249-sec-0115"> <h3 class="title" id="CD003249-sec-0115">Agreements and disagreements with other studies or reviews</h3> <p>Several potential reasons may explain why misoprostol randomised trials have not confirmed optimistic preliminary results from observational studies (<a href="./references#CD003249-bbs2-0024" title="Abdel‐AleemH , El‐NasharI , Abdel‐AleemA . Management of severe postpartum hemorrhage with misoprostol. International Journal of Gynecology &amp; Obstetrics.2001;72:75‐6. ">Abdel‐Aleem 2001</a>; <a href="./references#CD003249-bbs2-0030" title="AdekanmiOA , PurmessurS , EdwardsG , BarringtonJW . Intrauterine misoprostol for the treatment of severe recurrent atonic secondary postpartum haemorrhage. BJOG: an international journal of obstetrics and gynaecology2001;108:541‐2. ">Adekanmi 2001</a>; <a href="./references#CD003249-bbs2-0102" title="O'BrienP , El‐RefaeyH , GordonA , GearyM , RodeckCH . Rectally administered misoprostol for the treatment of postpartum haemorrhage unresponsive to oxytocin and ergometrine: a descriptive study. Obstetrics &amp; Gynecology1998;92:212‐4. ">O'Brien 1998</a>; <a href="./references#CD003249-bbs2-0103" title="OboroVO , TaboweiTO , BosahJO . Intrauterine misoprostol for refractory postpartum haemorrhage. International Journal of Gynecology &amp; Obstetrics2003;80:67‐8. ">Oboro 2003</a>). In previous reports, blood loss was subjectively assessed, but in the seven trials included in this review, blood loss was measured objectively. This is particularly important, as lack of blinding in previous studies may have affected the perception of effectiveness. The pharmacokinetics of misoprostol may also be a contributing factor: Variation in the route and dose of administration may result in significant variation in plasma therapeutic levels of the drug. Current evidence suggests that the oral route provides the advantage of rapid onset of action, although the vaginal and rectal routes confer the advantage of prolonged activity and greater bioavailability. The sublingual route possesses both of these advantages with a rapid onset of action, prolonged activity and greater bioavailability (<a href="./references#CD003249-bbs2-0025" title="Abdel‐AleemH , VillarJ , GulmezogluAM , MostafaSA , YoussefAA , ShokryM , et al. The pharmacokinetics of the prostaglandin E1 analogue misoprostol in plasma and colostrum after postpartum oral administration. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2003;108:25‐8. ">Abdel‐Aleem 2003</a>; <a href="./references#CD003249-bbs2-0037" title="AndolinaKL , TolosaJE , MonzoJM , RobertsNS , DalyS . Oral misoprostol is rapidly absorbed in postpartum women at term. Journal of Maternal‐Fetal &amp; Neonatal Medicine2003;14:229‐32. ">Andolina 2003</a>; <a href="./references#CD003249-bbs2-0058" title="DanielssonKG , MarionsL , RodriguezA , SpurBW , WongPY , BygdemanM . Comparison between oral and vaginal administration of misoprostol on uterine contractility. Obstetrics &amp; Gynecology1999;93:275‐80. ">Danielsson 1999</a>; <a href="./references#CD003249-bbs2-0079" title="HofmeyrGJ , WalravenG , GulmezogluAM , MaholwanaB , AlfirevicZ , VillarJ . Misoprostol to treat postpartum haemorrhage: a systematic review. BJOG: an international journal of obstetrics and gynaecology2005;112:547‐53. ">Hofmeyr 2005</a>; <a href="./references#CD003249-bbs2-0084" title="KhanRU , El‐RefaeyH . Pharmacokinetics and adverse‐effect profile of rectally administered misoprostol in the third stage of labour. Obstetrics &amp; Gynecology2003;101:968‐74. ">Khan 2003</a>; <a href="./references#CD003249-bbs2-0130" title="TangOS , SchweerH , SeyberthHW , LeeSW , HoPC . Pharmacokinetics of different routes of administration of misoprostol. Human Reproduction2002;17:332‐6. ">Tang 2002</a>; <a href="./references#CD003249-bbs2-0139" title="ZiemanM , FongSK , BenowitzNL , BanskterD , DarneyPD . Absorption kinetics of misoprostol with oral or vaginal administration. Obstetrics &amp; Gynecology1997;90:88‐92. ">Zieman 1997</a>). </p> <p>Misoprostol intake was associated with a significant increase in prostaglandin‐mediated side effects including maternal pyrexia (at least 38°C or at least 40°C), vomiting and shivering. Side effects appear to be dose dependent. Maternal pyrexia, in particular, is very rare when low‐dose misoprostol is used for induction of labour or termination of pregnancy (<a href="./references#CD003249-bbs2-0035" title="AlfirevicZ , WeeksA . Oral misoprostol for induction of labour. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD001338.pub2] ">Alfirevic 2006</a>; <a href="./references#CD003249-bbs2-0061" title="DoddJM , CrowtherCA . Misoprostol for induction of labour to terminate pregnancy in the second or third trimester for women with a fetal anomaly or after intrauterine fetal death. Cochrane Database of Systematic Reviews2010, Issue 4. [DOI: 10.1002/14651858.CD004901.pub2] ">Dodd 2010</a>). These side effects appear to be associated with high doses of misoprostol and may impact the management of patients with major obstetrical haemorrhage. For instance, blood transfusion forms an essential part of fluid resuscitation in women with major PPH, and a rise in body temperature following misoprostol use could be incorrectly labelled as a “transfusion reaction”, with subsequent stoppage of transfusion having a major impact on the general condition of the patient. Similarly, maternal pyrexia could mistakenly be labelled as “maternal sepsis”, which may result in the commencement of unnecessary intravenous antibiotic therapy. </p> <p>Three cases of deep vein thrombosis were reported in the <a href="./references#CD003249-bbs2-0003" title="Ducloy‐BouthersA , BroisinF , KeitaH , FontaineS , DepretS , LegoeffF , et al. Tranexamic acid reduces blood loss in postpartum haemorrhage. Critical Care2010;14()(Suppl 1):S124. Ducloy‐BouthorsAS , DuhamelA , BroisinF , KeitaH , FontaineS . Tranexamic acid reduces blood loss in post‐partum haemorrhage by reducing hyperfibrinolysis. British Journal of Anaesthesia2012;108:ii191. Ducloy‐BouthorsAS , DuhamelA , TournoysA , Prado‐DupontA , DebizeG , PeneauE , et al. Post‐partum haemorrhage induced hyperfibrinolysis. Thrombosis Research2013;131(Suppl 1):S89‐90. Ducloy‐BouthorsAS , JudeB , DuhamelA , BroisinF , HuissoudC , Keita‐MeyerH , et al. High‐dose tranexamic acid reduces blood loss in postpartum haemorrhage. Critical Care (London, England)2011;15(2):R117. ">Ducloy‐Bouthors 2011</a> study: two in the tranexamic acid group and one in the control group (RR 2.00, 95% CI 0.19 to 21.57). It is difficult to draw any conclusion regarding safety and risk of thromboembolic complications after tranexamic acid administration. It is noteworthy that several large studies did not observe any significant increase in the risk of thromboembolism (<a href="./references#CD003249-bbs2-0055" title="CRASH‐2 trial collaborators, ShakurH , RobertsI , BautistaR , CaballeroJ , CoatsT , et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH‐2): a randomised, placebo‐controlled trial. Lancet2010;376(9734):23‐32. ">CRASH‐2 trial collaborators 2010</a>; <a href="./references#CD003249-bbs2-0110" title="PeitsidisP , KadirRA . Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. Expert Opinion on Pharmacotherapy2011;12(4):503‐16. ">Peitsidis 2011</a>). </p> <p>In this current update, we have not included postrandomisation haemoglobin level or disseminated intravascular coagulopathy (DIC) as an outcome of interest for several reasons. First, blood and clotting factor transfusions form an essential part of any primary PPH resuscitation protocol in women with massive obstetrical haemorrhage. Therefore, a corrected haemoglobin level and/or clotting factors may simply confirm adequate resuscitation, rather than effectiveness of the uterotonics or the intervention. Second, postdelivery haemoglobin level is directly related to pre‐delivery levels rather than the impact of intervention on blood loss. Ideally, one should measure the drop in haemoglobin and/or hematocrit levels before delivery and the first blood transfusion. However, as primary PPH occurs unexpectedly, often among low‐risk women, pre‐delivery haemoglobin and/or hematocrit levels usually are not available. The trials by <a href="./references#CD003249-bbs2-0008" title="WinikoffB . Misoprostol for the treatment of postpartum hemorrhage. ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 20 February 2008). WinikoffB , DabashR , DurocherJ , DarwishE , NgocNTN , LeonW , et al. Treatment of postpartum hemorrhage with sublingual misoprostol versus oxytocin: results from a randomized, non‐inferiority trial among women not exposed to oxytocin during labor. International Journal of Gynecology &amp; Obstetrics2009;107(Suppl 2):S59. WinikoffB , DabashR , DurocherJ , DarwishE , NguyenTN , LeonW , et al. Treatment of post‐partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double‐blind, randomised, non‐inferiority trial. Lancet2010;375(9710):210‐6. ">Winikoff 2010</a>, <a href="./references#CD003249-bbs2-0001" title="BlumJ , WinikoffB , RaghavanS , DabashR , RamadanMC , DilbazB , et al. Treatment of post‐partum haemorrhage with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin: a double‐blind, randomised, non‐inferiority trial. Lancet2010;375(9710):217‐23. BlumJ , WinikoffB , RaghavanS , DabashR , RamadanMC , DilbazB , et al. Treatment of postpartum hemorrhage with sublingual misoprostol versus oxytocin: results from a randomized noninferiority trial among women receiving prophylactic oxytocin. International Journal of Gynecology &amp; Obstetrics2009;107(Suppl 2):S22‐S23. DaoB , BlumJ , BarreraG , Cherine RamadanM , DabashR , DarwishE , et al. Side effect profiles for misoprostol and oxytocin in the treatment of postpartum hemorrhage. International Journal of Gynecology &amp; Obstetrics2009;107(Suppl 2):S150. ">Blum 2010</a> and <a href="./references#CD003249-bbs2-0010" title="ZuberiNF , DurocherJ , SikanderR , BaberN , BlumJ , WalravenG . Misoprostol in addition to routine treatment of postpartum hemorrhage: a hospital‐based randomized‐controlled trial in Karachi, Pakistan. BMC Pregnancy and Childbirth2008;8:40. ">Zuberi 2008</a> have set an example by checking haemoglobin concentration for all labouring women before birth and after administration of the trial drug. However, this will be very difficult to replicate in other large pragmatic trials. Currently, lack of agreement has been noted between clinicians regarding the definition of DIC (<a href="./references#CD003249-bbs2-0069" title="GandoS , IbaT , EguchiY , OhtomoY , OkamotoK , KosekiK , et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Critical Care Medicine2006;34(3):625‐31. ">Gando 2006</a>). </p> <p>Two excluded quasi‐randomised trials from the same centre (<a href="./references#CD003249-bbs2-0015" title="SoltanMH , FaragallahMF , MosabahMH , Al‐AdawyAR . External aortic compression device: the first aid for postpartum hemorrhage control. Journal of Obstetrics and Gynaecology Research2009;35(3):453‐8. ">Soltan 2009</a>; <a href="./references#CD003249-bbs2-0016" title="SoltanMH , ImamHH , ZahranKA , AtallahSM . Assessing changes in flow velocimetry and clinical outcome following use of an external aortic compression device in women with postpartum hemorrhage. International Journal of Gynecology &amp; Obstetrics2010;110(3):257‐61. ">Soltan 2010</a>) evaluated the use of external aortic compression devices in addition to conventional therapy in the treatment of primary PPH. Investigators observed less blood transfusion when this device was used (RR 0.55, 95% CI 0.45 to 0.66), but the studies were too small to show an impact on other substantive outcomes. Although the use of external aortic compression devices was associated with abdominal discomfort and numbness and a tingling sensation, the lack of any short‐ or long‐term Ischaemic manifestations was quite reassuring. Currently, interest in evaluating the non‐pneumatic antishock garment (NASG) is growing, especially in low‐resource areas. With brief training, it appears that individuals without a medical background can use this first‐aid device. Miller and colleagues examined the use of NASG in a pre‐intervention/intervention study involving 1442 participants with hypovolaemic shock secondary to obstetrical haemorrhage from any cause and an estimated blood loss of at least 750 mL (<a href="./references#CD003249-bbs2-0093" title="MillerS , FathallaMM , OjengbedeOA , CamlinC , Mourad‐YoussifM , Morhason‐BelloIO , et al. Obstetric hemorrhage and shock management: using the low technology non‐pneumatic anti‐shock garment in Nigerian and Egyptian tertiary care facilities. BMC Pregnancy Childbirth2010;18:10‐64. ">Miller 2010</a>). The NASG intervention was associated with a significant reduction in measured blood loss, maternal mortality, severe morbidities and emergency hysterectomy. </p> <p>The question related to the management of women with major primary PPH who remain unresponsive to medical management with uterotonics and/or tranexamic acid therapy remains largely unanswered. In the absence of randomised controlled trials, clinicians are left to make their own judgement on the best combination of surgical, radiological and/or pharmaceutical interventions to control bleeding. Large double‐blind, multi‐centre, randomised controlled trials are needed to evaluate the effects of surgical interventions and/or radiological interventions on the primary outcome measures; however, the inability to obtain informed consent from critically ill patients may make it difficult to recruit participants. Clinicians should be encouraged to conduct such trials provided that they are able to follow agreed procedures for getting consent from critically ill patients and to ensure that recruitment does not interfere with standard clinical management. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003249-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003249-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/full#CD003249-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003249-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/full#CD003249-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 1 Maternal death." data-id="CD003249-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 1 Maternal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 2 Serious maternal morbidity." data-id="CD003249-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 2 Serious maternal morbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 3 Admission to intensive care unit." data-id="CD003249-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 3 Admission to intensive care unit. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 4 Hysterectomy." data-id="CD003249-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 4 Hysterectomy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 5 Average blood loss after enrolment in millilitres." data-id="CD003249-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 5 Average blood loss after enrolment in millilitres. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 6 Blood loss 500 mL or more after enrolment." data-id="CD003249-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 6 Blood loss 500 mL or more after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 7 Blood transfusion." data-id="CD003249-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 7 Blood transfusion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 8 Blood loss 1000 mL or more after enrolment." data-id="CD003249-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 8 Blood loss 1000 mL or more after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 9 Additional uterotonics." data-id="CD003249-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 9 Additional uterotonics. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 10 Manual removal of the placenta after enrolment." data-id="CD003249-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 10 Manual removal of the placenta after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 11 Uterine tamponade after enrolment." data-id="CD003249-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 11 Uterine tamponade after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 12 Artery ligation (uterine and/or hypogastric arteries) after enrolment." data-id="CD003249-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 12 Artery ligation (uterine and/or hypogastric arteries) after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 13 Arterial embolisation after enrolment." data-id="CD003249-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 13 Arterial embolisation after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 14 Uterine compression stitch after enrolment." data-id="CD003249-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 14 Uterine compression stitch after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 15 Evacuation of retained product of conception." data-id="CD003249-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 15 Evacuation of retained product of conception. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 16 Any surgical co‐interventions (uterine tamponade, artery ligations, arterial embolisation) excluding hysterectomy after enrolment." data-id="CD003249-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 16 Any surgical co‐interventions (uterine tamponade, artery ligations, arterial embolisation) excluding hysterectomy after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 17 Nausea." data-id="CD003249-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 17 Nausea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 18 Vomiting." data-id="CD003249-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 18 Vomiting. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 19 Diarrhoea." data-id="CD003249-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 19 Diarrhoea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 20 Maternal pyrexia 38 degrees or more." data-id="CD003249-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 20 Maternal pyrexia 38 degrees or more. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 21 Maternal pyrexia 40 degrees or more." data-id="CD003249-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 21 Maternal pyrexia 40 degrees or more. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 22 Headache." data-id="CD003249-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 22 Headache. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-001-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-001-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 23 Shivering." data-id="CD003249-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 23 Shivering. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-001-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-001-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 24 Feeling faint or fainting." data-id="CD003249-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 24 Feeling faint or fainting. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-001-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-001-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 25 Allergy." data-id="CD003249-fig-0027" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics, Outcome 25 Allergy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-001-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 1 Maternal mortality." data-id="CD003249-fig-0028" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 1 Maternal mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 2 Serious maternal morbidity." data-id="CD003249-fig-0029" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 2 Serious maternal morbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 3 Admission to intensive care." data-id="CD003249-fig-0030" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 3 Admission to intensive care. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 4 Hysterectomy." data-id="CD003249-fig-0031" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 4 Hysterectomy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 5 Blood loss 500 mL or more after enrolment." data-id="CD003249-fig-0032" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 5 Blood loss 500 mL or more after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 6 Mean blood loss after enrolment." data-id="CD003249-fig-0033" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 6 Mean blood loss after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 7 Blood loss 1000 mL or more after enrolment." data-id="CD003249-fig-0034" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 7 Blood loss 1000 mL or more after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 8 Blood transfusion within 24 hours." data-id="CD003249-fig-0035" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 8 Blood transfusion within 24 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 9 Duration from randomisation till cessation of bleeding or satisfactory response." data-id="CD003249-fig-0036" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 9 Duration from randomisation till cessation of bleeding or satisfactory response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 10 Additional uterotonics after enrolment." data-id="CD003249-fig-0037" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 10 Additional uterotonics after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 11 Examination under anaesthesia." data-id="CD003249-fig-0038" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 11 Examination under anaesthesia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 12 Uterine tamponade after enrolment." data-id="CD003249-fig-0039" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 12 Uterine tamponade after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 13 Bimanual compression." data-id="CD003249-fig-0040" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 13 Bimanual compression. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 14 Artery ligation (uterine and/or hypogastric arteries) after enrolment." data-id="CD003249-fig-0041" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 14 Artery ligation (uterine and/or hypogastric arteries) after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 15 Arterial embolisation after enrolment." data-id="CD003249-fig-0042" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 15 Arterial embolisation after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 16 Uterine tamponade after enrolment." data-id="CD003249-fig-0043" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 16 Uterine tamponade after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 17 Unsatisfactory response after enrolment after enrolment." data-id="CD003249-fig-0044" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 17 Unsatisfactory response after enrolment after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 18 Uterine compression stitch after enrolment." data-id="CD003249-fig-0045" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 18 Uterine compression stitch after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 19 Any surgical co‐interventions (uterine tamponade, artery ligations, arterial embolisation) excluding hysterectomy after enrolment." data-id="CD003249-fig-0046" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 19 Any surgical co‐interventions (uterine tamponade, artery ligations, arterial embolisation) excluding hysterectomy after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 20 Nausea." data-id="CD003249-fig-0047" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 20 Nausea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 21 Vomiting." data-id="CD003249-fig-0048" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 21 Vomiting. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 22 Diarrhoea." data-id="CD003249-fig-0049" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 22 Diarrhoea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 23 Headache." data-id="CD003249-fig-0050" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 23 Headache. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 24 Shivering." data-id="CD003249-fig-0051" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.24</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 24 Shivering. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 25 Feeling faint or fainting." data-id="CD003249-fig-0052" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.25</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 25 Feeling faint or fainting. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 26 Maternal pyrexia 38 degrees or more." data-id="CD003249-fig-0053" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.26</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 26 Maternal pyrexia 38 degrees or more. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 27 Maternal pyrexia 40 degrees or more." data-id="CD003249-fig-0054" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.27</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 27 Maternal pyrexia 40 degrees or more. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-002-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-002-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 28 Allergy." data-id="CD003249-fig-0055" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.28</div> <div class="figure-caption"> <p>Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 28 Allergy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-002-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rectal misoprostol versus combination of ergometrine and oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 1 Hysterectomy." data-id="CD003249-fig-0056" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Rectal misoprostol versus combination of ergometrine and oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 1 Hysterectomy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rectal misoprostol versus combination of ergometrine and oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 2 Persistent haemorrhage." data-id="CD003249-fig-0057" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Rectal misoprostol versus combination of ergometrine and oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 2 Persistent haemorrhage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rectal misoprostol versus combination of ergometrine and oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 3 Additional uterotonics." data-id="CD003249-fig-0058" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Rectal misoprostol versus combination of ergometrine and oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 3 Additional uterotonics. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rectal misoprostol versus combination of ergometrine and oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 4 Surgical co‐interventions (excluding hysterectomy)." data-id="CD003249-fig-0059" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Rectal misoprostol versus combination of ergometrine and oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome 4 Surgical co‐interventions (excluding hysterectomy). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Estrogen versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 1 Hysterectomy." data-id="CD003249-fig-0060" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Estrogen versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 1 Hysterectomy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Estrogen versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 2 Mean blood loss within two hours." data-id="CD003249-fig-0061" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Estrogen versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 2 Mean blood loss within two hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Estrogen versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 3 Mean blood loss between two and 24 hours." data-id="CD003249-fig-0062" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Estrogen versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 3 Mean blood loss between two and 24 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 1 Maternal mortality." data-id="CD003249-fig-0063" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 1 Maternal mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 2 Serious maternal morbidity (renal failure respiratory failure, cardiac arrest, multiple organ failure)." data-id="CD003249-fig-0064" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 2 Serious maternal morbidity (renal failure respiratory failure, cardiac arrest, multiple organ failure). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 3 Admission to intensive care unit." data-id="CD003249-fig-0065" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 3 Admission to intensive care unit. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 4 Hysterectomy." data-id="CD003249-fig-0066" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 4 Hysterectomy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 5 Blood loss 500 mL or more after enrolment." data-id="CD003249-fig-0067" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 5 Blood loss 500 mL or more after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 6 Blood loss 1000 mL or more after enrolment." data-id="CD003249-fig-0068" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 6 Blood loss 1000 mL or more after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 7 Total mean blood loss after enrolment." data-id="CD003249-fig-0069" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 7 Total mean blood loss after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 8 Blood transfusion within 24 hours." data-id="CD003249-fig-0070" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 8 Blood transfusion within 24 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 9 Additional uterotonics after enrolment." data-id="CD003249-fig-0071" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 9 Additional uterotonics after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 10 Unsatisfactory response after enrolment." data-id="CD003249-fig-0072" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 10 Unsatisfactory response after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 11 Uterine compression stitch after enrolment." data-id="CD003249-fig-0073" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 11 Uterine compression stitch after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 12 Interventions to control bleeding for secondary postpartum haemorrhage." data-id="CD003249-fig-0074" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.12</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 12 Interventions to control bleeding for secondary postpartum haemorrhage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 13 Examination under anaesthesia." data-id="CD003249-fig-0075" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.13</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 13 Examination under anaesthesia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 14 Uterine tamponade after enrolment." data-id="CD003249-fig-0076" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.14</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 14 Uterine tamponade after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 15 Artery ligation (uterine and/or hypogastric arteries) after enrolment." data-id="CD003249-fig-0077" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.15</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 15 Artery ligation (uterine and/or hypogastric arteries) after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 16 Arterial embolisation after enrolment." data-id="CD003249-fig-0078" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.16</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 16 Arterial embolisation after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 17 Headache." data-id="CD003249-fig-0079" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.17</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 17 Headache. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 18 Nausea." data-id="CD003249-fig-0080" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.18</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 18 Nausea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 19 Maternal pyrexia 38 degrees or more." data-id="CD003249-fig-0081" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.19</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 19 Maternal pyrexia 38 degrees or more. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 20 Maternal pyrexia 40 degrees or more." data-id="CD003249-fig-0082" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.20</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 20 Maternal pyrexia 40 degrees or more. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 21 Deep vein thrombosis." data-id="CD003249-fig-0083" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.21</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 21 Deep vein thrombosis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 22 Seizures." data-id="CD003249-fig-0084" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.22</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 22 Seizures. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 23 Dizziness." data-id="CD003249-fig-0085" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.23</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 23 Dizziness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 24 Phosphenes." data-id="CD003249-fig-0086" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.24</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 24 Phosphenes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 25 Secondary postpartum haemorrhage." data-id="CD003249-fig-0087" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.25</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 25 Secondary postpartum haemorrhage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 26 Surgical evacuation for secondary postpartum haemorrhage." data-id="CD003249-fig-0088" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.26</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 26 Surgical evacuation for secondary postpartum haemorrhage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 27 Intravenous iron therapy in the puerperium." data-id="CD003249-fig-0089" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.27</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 27 Intravenous iron therapy in the puerperium. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 28 Hospital re‐admission for secondary postpartum haemorrhage." data-id="CD003249-fig-0090" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.28</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 28 Hospital re‐admission for secondary postpartum haemorrhage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-005-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-005-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 29 Postnatal depression at day 42 postpartum." data-id="CD003249-fig-0091" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.29</div> <div class="figure-caption"> <p>Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH, Outcome 29 Postnatal depression at day 42 postpartum. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-005-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome 1 Maternal mortality." data-id="CD003249-fig-0092" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome 1 Maternal mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome 2 Serious maternal morbidity." data-id="CD003249-fig-0093" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome 2 Serious maternal morbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome 3 Hysterectomy." data-id="CD003249-fig-0094" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome 3 Hysterectomy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome 4 Blood loss 500 mL or more after enrolment." data-id="CD003249-fig-0095" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome 4 Blood loss 500 mL or more after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome 5 Blood loss 1000 mL or more after enrolment." data-id="CD003249-fig-0096" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome 5 Blood loss 1000 mL or more after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome 6 Average blood loss after enrolment." data-id="CD003249-fig-0097" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome 6 Average blood loss after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome 7 Blood transfusion." data-id="CD003249-fig-0098" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome 7 Blood transfusion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome 8 Other surgical interventions to control bleeding (other than hysterectomy)." data-id="CD003249-fig-0099" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome 8 Other surgical interventions to control bleeding (other than hysterectomy). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003249-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/urn:x-wiley:14651858:media:CD003249:CD003249-CMP-006-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_t/tCD003249-CMP-006-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome 9 Unsatisfactory response after enrolment." data-id="CD003249-fig-0100" src="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-006-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome 9 Unsatisfactory response after enrolment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/media/CDSR/CD003249/image_n/nCD003249-CMP-006-09.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="comparison" data-id="CD003249-tbl-0001"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Maternal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1881</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.16 [0.75, 50.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Misoprotol 600 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.08 [0.24, 105.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Misoprotol 200 mcg oral/400 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Misoprotol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.24 [0.38, 138.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious maternal morbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Misoprotol 600 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Admission to intensive care unit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.30, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Misoprotol 600 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.30, 2.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Hysterectomy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1881</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.16, 5.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Misoprotol 600 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.11, 4.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Misoprotol 200 mcg oral/400 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Misoprotol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.24 [0.38, 138.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Average blood loss after enrolment in millilitres <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.87 [‐23.63, 15.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Misoprotol 600 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [‐21.61, 23.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Misoprotol 200 mcg oral/400 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐85.0 [‐189.23, 19.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Misoprotol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.0 [‐50.78, 34.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Blood loss 500 mL or more after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.71, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Misoprotol 600 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.78, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Misoprotol 200 mcg oral/400 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.32, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Misoprotol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.21, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Blood transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1877</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.77, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Misoprotol 600 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.71, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Misoprotol 200 mcg oral/400 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.49, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Misoprotol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.70, 2.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Blood loss 1000 mL or more after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.42, 1.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Misoprotol 600 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.41, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Misoprotol 200 mcg oral/400 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.08, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Misoprotol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.08 [0.13, 74.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Additional uterotonics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1866</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.84, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Misoprotol 600 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.82, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Misoprotol 200 mcg oral/400 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.15, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Misoprotol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.80, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Manual removal of the placenta after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.44, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Misoprotol 600 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.44, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Uterine tamponade after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.07, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Misoprotol 600 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.07, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Artery ligation (uterine and/or hypogastric arteries) after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.14, 7.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Misoprotol 600 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.14, 7.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Arterial embolisation after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Misoprotol 600 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Uterine compression stitch after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Misoprotol 600 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Evacuation of retained product of conception <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.17 [0.25, 106.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Misoprotol 600 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 Misoprotol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.17 [0.25, 106.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Any surgical co‐interventions (uterine tamponade, artery ligations, arterial embolisation) excluding hysterectomy after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.15, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Misoprotol 600 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.15, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1643</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.84, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Misoprotol 600 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.87, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Misoprotol 200 mcg oral/400 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.15, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 Misoprotol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [1.16, 2.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Misoprotol 600 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [1.16, 2.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.37, 3.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Misoprotol 600 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.37, 3.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Maternal pyrexia 38 degrees or more <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1875</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [2.66, 3.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 Misoprotol 600 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.07 [2.61, 3.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 Misoprotol 200 mcg oral/400 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.23 [0.50, 168.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3 Misoprotol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.69 [1.29, 25.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Maternal pyrexia 40 degrees or more <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1715</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.58 [4.93, 37.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 Misoprotol 600 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.48 [4.91, 42.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.24 [0.38, 138.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1643</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.97, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 Misoprotol 600 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [1.01, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 Misoprotol 200 mcg oral/400 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.27, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Shivering <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1877</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [1.76, 2.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 Misoprotol 600 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.47 [0.93, 13.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 Misoprotol 200 mcg oral/ 400 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.95 [1.40, 6.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.3 Misoprotol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.14 [1.50, 3.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Feeling faint or fainting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.02, 8.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 Misoprotol 600 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.02, 8.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Allergy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 Misoprotol 600 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003249-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Maternal mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.06, 15.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.06, 15.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious maternal morbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Admission to intensive care <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Hysterectomy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [0.36, 10.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [0.36, 10.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Blood loss 500 mL or more after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [0.69, 4.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [0.69, 4.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mean blood loss after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>44.86 [26.50, 63.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>44.86 [26.50, 63.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Blood loss 1000 mL or more after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.65 [1.04, 6.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.65 [1.04, 6.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Blood transfusion within 24 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [1.02, 2.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [1.02, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Duration from randomisation till cessation of bleeding or satisfactory response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐1.02, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐1.02, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Additional uterotonics after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.57, 2.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.57, 2.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Examination under anaesthesia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.87, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.87, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Uterine tamponade after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.07, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 600 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.07, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 800 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Bimanual compression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.96, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.96, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Artery ligation (uterine and/or hypogastric arteries) after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Arterial embolisation after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Uterine tamponade after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Unsatisfactory response after enrolment after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.02, 0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.02, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Uterine compression stitch after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Any surgical co‐interventions (uterine tamponade, artery ligations, arterial embolisation) excluding hysterectomy after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.76, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.76, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.52 [1.45, 4.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.52 [1.45, 4.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.44, 4.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.44, 4.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.23, 4.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.23, 4.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Shivering <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [2.28, 3.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [2.28, 3.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Feeling faint or fainting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.73, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.73, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Maternal pyrexia 38 degrees or more <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [‐0.08, 0.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [‐0.08, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Maternal pyrexia 40 degrees or more <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>23.54 [0.50, 1104.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>23.54 [0.50, 1104.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Allergy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.14, 7.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 800 mcg misoprostol versus 40 IU oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.14, 7.09]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003249-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Rectal misoprostol versus combination of ergometrine and oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Hysterectomy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 800 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Persistent haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.04, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Additional uterotonics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.04, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Surgical co‐interventions (excluding hysterectomy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.15, 6.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Rectal misoprostol versus combination of ergometrine and oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003249-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Estrogen versus placebo/no treatment among women receiving conventional uterotonics for primary PPH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Hysterectomy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.01, 3.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mean blood loss within two hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐274.9 [‐384.72, ‐165.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mean blood loss between two and 24 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐50.7 [‐83.07, ‐18.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Estrogen versus placebo/no treatment among women receiving conventional uterotonics for primary PPH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003249-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Maternal mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious maternal morbidity (renal failure respiratory failure, cardiac arrest, multiple organ failure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Admission to intensive care unit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.6 [0.15, 2.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Hysterectomy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Blood loss 500 mL or more after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.97, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Blood loss 1000 mL or more after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.61, 2.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Total mean blood loss after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐91.0 [‐242.00, 60.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Blood transfusion within 24 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.24, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Additional uterotonics after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.76, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Unsatisfactory response after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [1.03, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Uterine compression stitch after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.2 [0.01, 4.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Interventions to control bleeding for secondary postpartum haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.11, 3.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Medical interventions to control bleeding (new subgroup)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.06, 15.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Surgical evacuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.05, 5.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Examination under anaesthesia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.97, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Uterine tamponade after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Artery ligation (uterine and/or hypogastric arteries) after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Arterial embolisation after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.8 [0.22, 2.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.0 [1.46, 82.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Maternal pyrexia 38 degrees or more <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.52, 2.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Maternal pyrexia 40 degrees or more <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.19, 21.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Dizziness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.31, 5.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Phosphenes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.0 [0.88, 18.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Secondary postpartum haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.06, 15.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Surgical evacuation for secondary postpartum haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.05, 5.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Intravenous iron therapy in the puerperium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.89, 2.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Hospital re‐admission for secondary postpartum haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.05, 5.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Postnatal depression at day 42 postpartum <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003249-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Lower uterine segment compression versus conventional treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Maternal mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious maternal morbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Hysterectomy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Blood loss 500 mL or more after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.02, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Blood loss 1000 mL or more after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.2 [0.01, 4.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Average blood loss after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐103.00 [‐260.00, 52.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Blood transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.33 [0.66, 8.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Other surgical interventions to control bleeding (other than hysterectomy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Unsatisfactory response after enrolment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.15, 6.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Lower uterine segment compression versus conventional treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003249.pub3/references#CD003249-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003249.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003249-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003249-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003249-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD003249-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003249-note-0003">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003249\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003249\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003249\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003249\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003249\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003249\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003249\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003249\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003249\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003249\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003249\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003249\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003249\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003249\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003249\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003249\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003249\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003249\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PrHmaMrX&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003249.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003249.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003249.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003249.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003249.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725622979"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003249.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725622983"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003249.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e7fbb8f5ff466',t:'MTc0MDcyNTYyMy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 